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ABSTRACT 
BACKGROUND: 
Hypertensive Disorders in pregnancy represents the most common medical 
complication of pregnancy which affects 7-15% of all gestations.WHO reports 
16% of maternal deaths due to Hypertensive disease.Preeclampsia accounts for 
more than half of the cases.It is a disorder with course being progressive and 
continuous affecting virtually every organsystem.So it should be detected at an 
earlier stage so that appropriate management can be undertaken to prevent 
maternal and fetal morbidity and mortality.Preeclampsia is a multisystem 
disorder with lot of cellular death.LDH being an intracellular enzyme gets 
elevated in serum due to leakage of enzyme from inside the cells.Uric acid 
levels are raised in preeclampsia due to its reduced renal clearance.Hence this 
study was done to correlate serum LDH and uric acid levels with the severity of 
preeclampsia,Maternal and Fetal outcomes. 
MATERIALS AND METHODS: 
         This study was a comparative observational study conducted among 165 
Antenatal women in third trimester attending Antenatal OPD/Labour ward at 
Stanley Medical College during January to September 2015 after getting ethical 
clearance from the Institute Ethics Committee.Study group included 50 
Normotensives,48 Mild preeeclamptics,53 Preeclamptics and 14 Eclamptics 
classified based on NHBPEP classification.Clinical History obtained as in 
structured proforma.After Informed consent from patients,blood samples were 
taken for Serum LDH,Uric acid estimation by IFCC and Uricase method 
respectively. 
Study group were divided into 3 subgroups based on LDH levels(<600IU/L, 
600-800IU/L, >800IU/L) and based on uric acid levels(<6mg%, >6mg%). LDH 
and Uric acid values were compared with diagnostic components of 
preeclampsia such as Systolic BP,DiastolicBP,Proteinuria Gestational age at 
delivery,mode of delivery,birth weight of babies,maternal complications like 
Abruption,HELLP,Eclampsia,Pulmonaryedema,Intracranial Haemorrhage, 
Maternal death,Fetal complications like IUD, IUGR.The results were compared 
based on One Way Analysis of Variance,chi-square test and differences were 
considered as significant when p<0.05. 
OBSERVATION AND RESULTS: 
In our study,Extremes of age group(<19yrs,>30yrs) patients had increase 
severity of preeclampsia. Majority(55%) of patients were Primigravida.There 
was no association between parity and LDH,Uric acid levels.Among patients 
with LDH>800IU/L,98% patients had systolic BP>160mmHg.LDH level and 
systolic BP found to have significant association.Among patients with LDH 
600-800IU/L and >800IU/L,60% and 96% respectively had Diastolic 
BP>110mmHg(P value< 0.001).Increasing LDH levels were associated with 
increasing severity of proteinuria(P<0.001).There was reduction in mean 
gestational age at delivery(<36 weeks) and mean birth weight of babies  in 
groups with higher LDH levels propably due to more number of preterm 
deliveries in view of severity of preeclampsia.Groups with higher LDH 
levels(600-800 and >800IU/L) had more maternal and fetal 
complications(p<0.05).All those diagnostic variables were compared with uric 
acid levels.Group with uric acid >6mg% had significant association with 
Systolic BP,DiastolicBP,Proteinuria,Mean birth weight of babies,maternal and 
fetal morbidity and mortality. 
CONCLUSION: 
 Serum LDH and uric acid values were significantly high in pre-eclamptic 
patients depending on the severity of the disease indicating the increased 
cellular turnover in them. Higher LDH and uric acid levels was associated with 
diagnostic components of preeclampsia. Hence diagnostic and management 
strategies may be considered based on S.LDH and uric acid levels and further 
studies on a larger sample can be done to substantiate our observations on the 
utility of this parameter as a diagnostic and prognostic component of 
preeclampsia. Development of new management strategies based on S. LDH 
and uric acid levels may help in appropriate decision making thereby avoiding 
unwanted maternal &fetal deaths.   
KEYWORDS : 
LDH, Uric Acid, Preeclampsia, eclampsia 
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INTRODUCTION 
Hypertensive disorders represents the most common medical 
complication of pregnancy which affects about 7 – 15 % of all 
gestations1.According to World Health Organization(WHO) 16% of 
maternal deaths were reported due to Hypertensive disease which is 
higher in proportion than the other leading causes such as Haemorrhage, 
Sepsis2. 
           Of these Hypertensive disorders, Preeclampsia syndrome alone or 
if superimposed with chronic hypertension is most dangerous. However 
Gestational Hypertension is followed by signs of Preeclampsia in almost 
half cases. Preeclampsia syndrome is a pregnancy-specific syndrome that 
affects virtually every organ system. Disease course is progressive and 
continuous which gets arrested only by termination of pregnancy. So the 
disease should be detected at an earlier stage with several Biochemical 
markers and predictive tests so that appropriate management can be 
undertaken. 
           Several biochemical markers have been proposed to identify the 
women who destined to develop Preeclampsia which were chosen on the 
basis of pathophysiological abnormalities associated with Preeclampsia 
which includes markers of Placental Dysfunction, Endothelial cell 
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dysfunction, angiogenesis, coagulation activation, markers of systemic 
inflammation3.  
Pre eclampsia- eclampsia is a multi system disorder that leads to lot 
of cellular death. Lactic Acid Dehydrogenase (LDH) is an Isoenzyme 
which is intracellular in location which helps in interconversion of 
pyruvate and lactate inside cells. Any cellular death results in leakage of 
enzyme from the cell and rise in serum in LDH levels. Hence serum LDH 
levels is used to assess the extent of cellular damage and   severity of pre 
eclampsia4. 
             Uric acid, which is one of the end product of purine metabolism 
is elevated in patients of pre eclampsia because of decreased renal 
clearance and increased production5.  Decreased renal clearance is due to 
altered renal tubular function and Overproduction of uric acid due to 
increased breakdowns of purines in placenta. This uric acid impairs nitric 
oxide production which results in endothelial cell dysfunction which 
plays a role in pathophysiology of Preeclampsia. 
                 Estimation of serum LDH and Uric Acid level is a simple 
biochemical test, which quantitates the extent of cellular death and 
thereby the assessment of severity of preeclampsia. 
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AIM AND OBJECTIVES 
  
1. To compare serum LDH and Uric Acid levels in normotensive  
pregnant women and in women with preeclampsia-eclampsia. 
 
2. To correlate serum LDH and Uric acid levels with severity of 
disease, maternal and perinatal outcome. 
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REVIEW OF LITERATURE 
According to National High Blood Pressure Education  Program 
Working Group(NHBPEP) and ACOG6,7, Hypertension is  defined as  
1) Systolic BP of ≥ 140 mmHg and/or 
2)  Diastolic BP of ≥ 90 mmHg (Korotkoff V) that is  measured in 
2 occasions 4 – 6 hours apart within 7 days period. Increase in 30mmHg 
systolic or 15 mmHg Diastolic above the  patient’s baseline abandoned as 
the diagnostic criteria in HTN as it is  not proved to be good prognostic 
indicator. However close monitoring is needed in those patients. 
Preeclampsia is a multiorgan disease of unknown etiology that  
leads to development of Hypertension and Proteinuria after 20 weeks of 
gestation.Classically defined as the triad of Hypertension, edema and 
proteinuria.But recent defnitions does not include edema due to lack of 
specificity.Appearance of proteinuria remains an important Diagnostic 
criteria in differentiating Preeclampsia from Gestational Hypertension. 
Proteinuria is defined as  
 24 Hour urine protein excretion exceeding 300mg 
 Urine Protein:Creatinine ratio ≥0.3(30mg/mmol)  or        
  Persistent 30mg/dl(Urinary dipstick of 1+ in random urine 
samples). 
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CLASSIFICATION OF HYPERTENSIVE DISORDERS IN 
PREGNANCY: 
According to International Society for the Study of Hypertension in 
Pregnancy (ISSHP), Hypertensive disorders during pregnancy is 
classified into 4 defined groups as follows: 
1. Gestational Hypertension 
2. Preeclampsia and Eclampsia 
3. Chronic Hypertension  
 Essential 
 Secondary 
4. Preeclampsia superimposed on Chronic Hypertension. 
GESTATIONAL HYPERTENSION: 
        New onset hypertension developing after 20 weeks of gestation, 
during labour or in the first 24 hour postpartum without proteinuria or any 
other systemic  features of preeclampsia in a previously normotensive 
nonproteinuric women and the Blood Pressure resolves within 3 months 
of postpartum. 
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PREECLAMPSIA: 
       Hypertension associated with proteinuria > 0.3 gm/L in a 24 hour 
urine collection (or) 1+ by qualitative urine examination ,after 20 weeks 
of gestation. 
ECLAMPSIA: 
Convulsions occurring in a patient with preeclampsia. 
CHRONIC HYPERTENSION: 
 It is defined as Hypertension present before 20 weeks of pregnancy 
or that is diagnosed preconceptionally. Blood pressure elevation that 
persists more than 12 weeks postpartum is also retrospectively considered 
as Chronic Hypertension. 
 ESSENTIAL HYPERTENSION is diagnosed when there is no 
apparent underlying cause for chronic hypertension. 
 SECONDARY HYPERTENSION may be caused by renal 
parenchymal disease, renovascular disease, endocrine disorders or 
coarctation of aorta. 
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PREECLAMPSIA SUPERIMPOSED ON CHRONIC 
HYPERTENSION: 
It is diagnosed when one or more features of preeclampsia 
develops for first time during pregnancy after 20 weeks of gestation in a 
women with pre-existing chronic hypertension. 
NICE GUIDELINES8: 
Hypertension is classified according to severity as follows: 
1) MILD HYPERTENSION:  Systolic Blood pressure 140-149 
mmHg, Diastolic Blood Pressure 90 – 99 mmHg. 
2) MODERATE HYPERTENSION:  Systolic Blood pressure  
150-159 mmHg, Diastolic Blood Pressure 100-109 mmHg. 
3) SEVERE HYPERTENSION: Systolic Blood PRESSURE 160 
mmHg or greater, Diastolic Blood Pressure 110mmHg or greater. 
RISK FACTORS FOR PREECLAMPSIA9: 
COUPLE RELATED RISK FACTORS: 
 Primipaternity 
 Limited sperm exposure 
 Pregnancy after donor insemination, donor egg, donor embryo 
 Dangerous male partner 
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MATERNAL OR PREGNANCY RELATED RISK FACTORS: 
 Extremes of Age(Teenage and > than 35 years) 
 Parity 
 Interval from last pregnancy greater than 10 years 
 Obesity 
 Insulin resistance/Gestational Diabetes 
 Smoking 
 Multifetal pregnancy 
 Hydrops fetalis 
 Hydatiform mole 
 Preeclampsia in previous pregnancy 
 Family history of Preeclampsia 
 Maternal Low birth weight 
 Abnormal Uterine artery Doppler at 18 to 24 weeks. 
 
PREEXISTING MEDICAL DISEASE: 
 Pre-Gestational Diabetes 
 Chronic Hypertension or Renal disease. 
 Maternal  Immunologic Disease 
 Preexisting Thrombophilia, Antiphospholipid antibody Syndrome 
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ETIOPATHOGENESIS OF PREECLAMPSIA: 
1) ABNORMAL TROPHOBLASTIC INVASION: 
It can be explained by Two-Stage Disorder Hypothesis10. 
FIRST STAGE occurs before 12 weeks postfertilization ,upto the 
interface between decidua and Myometrium.First stage involves 
Endovascular Invasion of spiral arteries by Trophoblastic cells.This 
migration transforms the small musculoelastic spiral arteries into Large 
Tortuous channels that carry large amount of blood to the Intervillous 
space and are resistant to the effects of Vasomotor agents.These 
Physiologic changes are incomplete in patients of Preeclampsia and 
Trophoblastic invasion affects only in some of the spiral arteries and does 
not progress into Myometrial portion of the arteries (INCOMPLETE 
TROPHOBLASTIC INVASION).This deficiency results in decreased 
UteroPlacental Perfusion. 
SECOND STAGE occurs normally between 12 and 16 weeks of 
gestation which involves invasion of intramyometrial segments of 
spiralarteries.In Preeclampsia, second stage involves the conversion of 
previous Uteroplacental Maladaptation to  MATERNAL SYSTEMIC 
SYNDROME  of Preeclampsia which is associated with Endothelial cell 
activation and generalised Hyperinflammatory state. This anatomic and 
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physiologic disruption of normal placentation lead to release of placental 
debris from the Intervillous space into the Maternal circulation, thereby 
inciting a Systemic Inflammatory response by stimulating the synthesis of 
Inflammatory Cytokines, products that affects Angiogenesis and 
Abnormal Lipid Peroxidation. Severity of Hypertensive disorder is 
correlated with the magnitude of abnormal Trophoblastic Invasion11. 
 
ABNORMAL TROPHOBLASTIC INVASION 
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2) ENDOTHELIAL DYSFUNCTION AND VASOSPASM12: 
 
 
 
 
3)  
 
 
Placental ischemic changes in preeclampsia 
 
 
Causes Release of Inflammatory cytokines like TNF-α,IL and 
antiangiogenic factors. This causes oxidative  
stress which leads to formation of Lipid Peroxides  
which injures Endothelial cells 
 
Endothelial Cell Injury And Inturn Increased  
Capillary Permeability 
 
This triggers Platelet Aggregation and Increased Thrombin and 
Fibrin Formation.In normal pregnancy both coagulation and 
fibrinolytic activity is increased but in Preeclamptic patients, 
Coagulant activity is much increased. 
 
Microvascular coagulation manifests by 
Thrombocytopenia.Increased vascular permeability manifests by 
edema and proteinuria. 
 
  
Increased vascular 
sensitivity to 
Vasopressors esp 
Angiotensin
Decreased perfusion to 
Haemorrhage,Necrosis 
and end organ damage
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ENDOTHELIAL 
DYSFUNCTION
-II
Generalized and 
intense 
vasospasm
all body organs
Increased  Peripheral 
HYPERTENSION
Decreased Prostacyclin
Increased 
ThrombaxaneA2
 
resistance
Decreased NO Synthesis
Increased vascular 
Endothelin-1
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3) IMMUNOLOGIC FACTORS13: 
In preeclamptics, there is loss of Maternal tolerance to paternally 
derived placental and fetal antigens. The placenta being fetal origin has 
both maternal, paternal haplotypes and Genetic determitants. Of the 
Histocompatibility Antigens only HLA-G, an immunosuppressive antigen 
is expressed on the surface of trophoblasts which is a placental cell most 
intimate to the maternal system. 
In Preeclamptics, there is lower level of messenger RNA for HLA-
G leading reduced expression of HLA-G on trophoblasts. This causes 
Immune Maladaptation in Preeclampsia. 
4) GENETIC FACTORS14: 
The hereditary predisposition to develop preeclampsia syndrome is 
the result of complex interaction of several genes which includes both 
maternal and paternal. Thus Preeclampsia is multifactorial and polygenic 
in origin. Genes that are in positive association with Preeclampsia 
syndrome are as follows: 
 MTHFR Gene which affects Methyl TetraHydroFolateReductase. 
 HLA 
 F5(Factor V Leiden) 
 F2(Prothrombin) 
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 AGT(Angiotensinogen) 
 NOS3(Endothelial Nitric Oxide) 
 ACE(Angiotensin Converting Enzyme) 
 CTLA4(Cytotoxic T-Lymphocyte Associated Protein) 
 LPL(Lipoprotein Lipase) 
 SERPINE-1(Serine Peptidase Inhibitor). 
 
5) ANGIOGENIC IMBALANCE: 
In preeclampsia, due to worsening Hypoxia at the uteroplacental 
interface, there is excessive production of AntiAngiogenic peptides 
especially following 2 peptides.    
a) Soluble Fms-like Tyrosine Kinase 1(sFlt-1) 
b) Soluble Endoglin(sEng) 
 
a) Soluble Fms-like Tyrosine Kinase 1(sFlt-1)15: 
     It is a variant of Flt-1 receptor for placental growth factor and 
VEGF. Increased maternal sFlt-1 levels inactivate and decrease PIGF 
and VEGF concentrations leading to endothelial dysfunction. 
 
b) Soluble Endoglin(sEng)16: 
It is a placenta derived 65-kDamolecule that blocks 
endoglin, which is a surface coreceptor for TGFβ Family.Also 
 called CD105, soluble form of end
isoforms from binding to endothelial receptors thatresults in 
decreased nitric oxide dependent vasodilatation.
 
ANTIANGIOGENIC PROTIENS
6) RENIN-ANGIOTENSIN
The RAAS axis maintains sodium concentration
and Blood Pressure.
concentration, Angiotensin
But there is refractoriness
who are destined to be
15 
oglin inhibits various TGF
 
 
-ALDOSTERONE SYSTEM(RAAS)
 In normal pregnancy, Renin activity,
-II levels, Aldosterone levels 
 to the effects of Angiotensin
 Preeclamptic, there is a loss of Refractoriness
β 
 
17: 
, Blood volume 
 plasma renin 
are increased. 
-II. In women 
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due to down regulation of Angiotensin receptors in the presence of 
persistently elevated levels. 
PATHOPHYSIOLOGICAL CHANGES: 
It involves multiple organ systems described as follows. 
1) CARDIOVASCULAR  SYSTEM: 
In Preeclampsia, due to increased peripheral resistance18, there is 
decreased cardiac output that results in Hyperdynamic ventricular 
function. Pulmonary Edema results from Alveolar Endothelial-Epithelial 
leak.  
Generalised Vasoconstriction causes increased vascular 
permeability and leakage of plasma into interstitial space that results in 
reduced plasma volume and HAEMOCONCENTRATION.  
2) COAGULATION: 
Coagulation abnormalities seen in Severe Preeclampsia and Eclampsia 
patients, It includes Thrombocytopenia, Reduced levels of clotting 
factors, evidence of platelet activation, Intravascular coagulation and 
Haemolysis. Thrombocytopenia defined by platelet count less than 1 lakh 
indicates severe disease. Haemolysis demonstrated by increase in LDH 
levels, peripheral smear showing schistocytosis, spherocytosis, 
17 
 
reticulocytosis19.These abnormalities results from Microangiopathic 
Haemolysis. The association of Thrombocytopenia, Haemolysis along 
with Elevated Liver Enzymes is referred as HELLP SYNDROME. 
3) RENAL CHANGES: 
Due to increased afferent arteriolar resistance there is reduced renal 
blood flow and reduced GFR. This results in elevated plasma Uric Acid. 
Urine sodium concentration is increased and urinary excretion of 
calcium is decreased due to increased tubular reabsorption. 
PROTEINURIA is the hallmark of preeclampsia. ACUTE RENAL 
FAILURE due to tubular necrosis is rare and it is usually induced by 
Hypotension and Hypovolaemia in severe disease. 
Preeclampsia produce a characteristic changes in kidneys termed as 
‘GLOMERULAR CAPILLARY ENDOTHELIOSIS’, and 
‘EARLYFOCAL SEGMENTAL GLOMERULAR SCLEROSIS20,21’ 
in some patients. These lesions usually resolves completely after 
pregnancy. 
4) LIVER: 
Excessive fibrin deposition in hepatic sinusoids obstructs blood 
flow and hepatic vasoconstriction causes the release of hepatic enzymes 
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(AST, ALT, LDH) in circulation. Characteristic lesions in liver are 
PERIPORTAL HAEMORRHAGES IN THE LIVER PERIPHERY. 
Hepatic vasculature in the subcapsular region is particularly 
susceptible resulting in subcapsular haemorrhages which becomes larger 
and forms SUBCAPSULAR HAEMATOMAS and liver rupture. 
5) BRAIN: 
Both intense vasospasm of cerebral arterioles and over-dilatation of 
vessels are implicated in the pathogenesis of Eclampsia. In hypertension, 
as a part of auto regulatory mechanism, cerebral vasoconstriction occurs 
which leads to Ischaemia, Edema, Infarction. When the regulatory 
mechanisms fails at some point, dilatation of vessels occurs resulting in 
Hyperperfusion and ‘VASOGENIC EDEMA22’ 
The Pathognomic finding in preeclampsia is EDEMA with FOCI 
OF INFARCTION. 
CEREBRAL HAEMORRHAGE should be suspected in older 
gravida with Chronic Hypertension and patients presents with 
Hemiplegia, focal deficits, coma following eclampsia. CT/MRI should be 
done to confirm the diagnosis. 
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BLINDNESS23 can occur due to: 
 Severe Papilloedema 
 Retinal Detachment 
 Occipital lobe lesions 
6) PLACENTA: 
Placenta of Hypertensive patients shows increased evidence of 
Infarct, Congested chorionic villi, Haematoma, and Proliferative 
endarteritis. 
Microscopic examination shows increased syncytial knots, 
fibrinoid necrosis, cytotrophoblastic cellular proliferation, calcified and 
hyalinised villous spots24, endothelial proliferation. 
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COMPLICATIONS OF PREECLAMPSIA: 
 MATERNAL 
 FETAL 
            MATERNAL                                 FETAL 
1) Abruptio Placenta(Most 
common) 
1) IUGR 
2) HELLP Syndrome 2) Prematurity 
3) Pulmonary Edema 3) Antepartum and 
Intrapartum Asphyxia 
4) Thrombocytopenia/DIC 4) Intrauterine Death 
5) Acute Renal Failure   
6) ARDS(Adult Respiratory 
Distress Syndrome) 
  
7) ECLAMPSIA   
8) Hepatic Rupture   
9) Cerebral Haemorrhage   
10) Sudden Postpartum Collapse   
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PREDICTIVE TESTS FOR THE DEVELOPMENT OF 
PREECLAMPSIA SYNDROME: 
TESTING 
RELATED TO: 
TESTS: 
Placental perfusion/ 
Vascular Resistance 
Roll-over test25,Isometric handgrip test, pressor response 
to Angiotensin-II infusion25,Midtrimester mean arterial 
blood pressure26, 24 hour ambulatory BP monitoring, 
Uterine artery Doppler velocimetry, pulse wave 
analysis26. 
Fetoplacental unit 
Endocrine 
dysfunction 
αFetoprotein, HCG26, Estriol, PAPP-A, inhibin A,     
Activin A, placental protein 13,CRH. 
Renal Dysfunction 
Serum URIC ACID26, Microalbuminuria, Urinary 
Calcium26, microtransferrinuria, Cystatin C. 
Endothelial 
dysfunction / 
oxidative stress 
Platelet count and activation,LDH,Fibronectin27,PG’s , 
prostacyclins, Thrombaxane, CRP, Cytokines, 
Endothelins, Homocysteine, APLA, VEGF, PIGF,  
sFlt-1. 
Others 
AntithrombinIII, ANP, β2microglobulin, haptoglobin, 
cell free fetal DNA, serum and urine proteomics, 
Hepatic aminotransferases. 
22 
 
UTERINE ARTERY DOPPLER VELOCIMETRY: 
In normal pregnancy, impedance to uterine artery blood flow is 
reduced. In preeclampsia, failure of trophoblastic invasion into vessels is 
reflected by High impedance to uterine blood flow. Increased resistance 
to flow and presence of Diastolic Notch is indicative of 
PREECLAMPSIA. Whereas in Chronic HTN, it is predictive of 
superimposed Preeclampsia. Other indices like PULSATALITY INDEX, 
RESISTANCE INDEX are noted. Recent studies shows combined use of 
Doppler studies and biochemical markers in 1st trimester have shown 
improved rates of prediction for preeclampsia26,28,29.. 
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PREVENTION OF PREECLAMPSIA: 
 
 
 
 
PREVENTION 
OF 
PREECLAMPSIA
DIETARY 
MODIFICATION
EXERCISE
ANTIOXIDANTS
ANTITHROMBOTIC 
DRUGS
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1) DIETARY MODIFICATION:  
• LOW SALT DIET: Earliest researches found that salt restriction 
is useful in preventing preeclampsia. However recent trial 
(Knuist,1998) proved that salt restricted diet is ineffective in 
preventing preeclampsia30. 
• CALCIUM SUPPLEMENTATION : Calcium supplementation 
of 1.5 – 2 gms reduces the incidence of preeclampsia by half31. 
• ZINC SUPPLEMENTATION: Low serum Zinc levels associated 
with suboptimal outcomes of pregnancy including preeclampsia. 
However, Cochrane review (2012) does not reveal any evidence of 
improved pregnancy outcome with Zinc supplementation32. 
• FISHOIL SUPPLEMENTATION: Supplementation of common 
dietary sources such as EPA (Eicosapentaenoic acid), ALA 
(Alphalinoleic acid), DHA (Docosahexaenoic acid) would prevent 
inflammatory mediated Atherogenesis. But no trials conducted so 
far have shown to prevent preeclampsia  
• L-ARGININE: Nitric oxide, potent vasodilator produced from L-
arginine by endothelial cells. Supplementation of L-Arginine does 
not shown to prevent preeclampsia. 
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2) EXERCISE:  
Exercise and physical activity have shown to prevent Hypertension 
in non-pregnant women.But studies have not shown  to proven benefit in 
preeclampsia33. 
3) ANTITHROMBOTIC DRUGS:  
Aspirin being an Antiplatelet aggregator improves the blood flow 
by preventing the formation of microthrombi within the blood vessels. A 
large RCT ‘Collaborative Low Dose Aspirin Study in Pregnancy’ 
(CLASP TRIAL34) shows non-significant reduction of 12% in 
Preeclampsia, but there was a significant reduction of proteinuric 
preeclampsia in women prone to develop early onset preeclampsia. A 
recent metaanalysis shows earlier the aspirin started in pregnancy, greater 
was the benefit in reducing preeclampsia. NICE recommends 75mg of 
Aspirin daily for all women who are at High risk for preeclampsia 
from 12 weeks until Birth of the baby35. 
4) ANTIOXIDANTS :  
A small RCT using vitamin C and E in women at 20 weeks of 
gestation shows significant decrease in incidence of preeclampsia in 
treated group. However, a second study does not show a significant 
difference. 
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INDICATORS OF SEVERITY OF PREECLAMPSIA: 
ABNORMALITY 
NON-
SEVERE(MILD) 
SEVERE 
PREECLAMPSIA36 
Systolic BP 140 to <160mmHg ≥160mmHg 
Diastolic BP 90 to <110mmHg ≥110mmHg 
Proteinuria 
Persistent 1+ to 2+ in 
dipstick,>0.3gm to 
<5gm in 24 hours 
3+ or more on dipstick 
>5g in 24 hours 
Headache Absent Present 
Visual Disturbances Absent Present 
Upper Abdominal 
Pain 
Absent Present 
Convulsions Absent Present 
Oliguria Absent Present 
Serum Creatinine Normal Elevated(>1.2mg/dl) 
Serum Transaminase Minimal Marked 
Thrombocytopenia 
(< 100,000/µl) 
Absent Present 
IUGR Absent Obvious 
Pulmonary edema Absent Present 
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MANAGEMENT OF PRE-ECLAMPSIA: 
The only Effective definitive treatment of Preeclampsia is 
DELIVERY. Although delivery is always beneficial for the mother, it 
may not be optimal for the premature fetus. Once the diagnosis of 
Preeclampsia is made, the Management depends upon,      
 Severity of Preeclampsia 
 Gestational Age of the Fetus 
 Maternal and Fetal status at the time of initial evaluation 
 Presence or absence of Labour 
 Level of specialized Neonatal Services 
MILD PREECLAMPSIA: 
The recent NICE guidelines37 suggests that all patients initially 
diagnosed with Preeclampsia must be admitted to the hospital for 
Evaluation. The first step in the management is Assessment of 
Gestational Age. The Goal of management in Mild Preeclampsia is Early 
detection of progression to severe Preeclampsia and organ dysfunction. 
Antihypertensive drugs use in mild Preeclampsia is Questionable. NICE 
Clinical guidelines37 suggest treating moderate Hypertension of BP 
150/100 – 159/109 mmHg with Antihypertensives to keep BP < 150/80-
100 range. First line  AntiHypertensive in this situation is Oral Labetalol, 
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given orally in doses of 100-400mg every 8-12 hours. Alternatives are 
MethylDopa or Nifedipine. 
 
GESTATIONAL AGE
<32 WEEKS
YES
In-patient 
management
32 - 36 WEEKS
Initial Assessment:
BP≥150/100
Proteinuria>1gm/24 hrs
Platelets<1 lakh
Oligo,IUGR
Elevated UA S/D Ratio
Severe symptoms,unreliable patient
NO
Outpatient  
management 
MATERNAL SURVEILLANCE:
Daily Blood Pressure 4 times/day,
Maternal weight gain,Daily urine Dipstick,
Platelets,Liver Enzymes,Serum Creatinine twice weekly,Questioning for Imminent  symptoms
FETAL SURVEILLANCE:
Daily Fetal Kick Count,NST with Liquor Assessment weekly/biweekly,
Fetal Biometry every 3 weeks,Umbilical and cerebral Doppler 2 weekly/weekly if there is growth restriction.
UNSTABLE
STEROIDS AND 
EARLY DELIVERY
STABLE
Continue expectancy till 37 weeks
Favourable cervix
For ARM and SYNTO
Unfavourable cervix
Ripen with PGE2 Gel
Obstetric Indication
FOR LSCS
≥37 WEEKS
DELIVERY
NO
no
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MANAGEMENT OF SEVERE PREECLAMPSIA: 
The Management of Severe Preeclampsia depends upon the 
Gestational Age 
 <24 weeks = Seizure prevention, Blood Pressure control, and 
Immediate Delivery. 
 25 – 33 weeks = Expectant Management by Maternal and Fetal 
Surveillance, AN steroid therapy for fetal Lung Maturity, Deliver if 
there is maternal and fetal indication. 
 > 34 weeks= Seizure prevention, Blood pressure control, 
immediate delivery. 
 
MATERNAL SURVEILLANCE: 
 Blood Pressure 4 times/day 
 Daily  Input and Output 
 Urine Albumin once a day,24 Hour urinary protein 
 Daily Maternal weight  
 Platelet count, RFT, LFT Biweekly 
 Coagulation Profile 
 AntiHypertensive treatment, Steroids 
 Questioning for Imminent symptoms 
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 Fundoscopy 
FETAL SURVEILLANCE: 
 Daily Fetal Kick Count 
 Non stress Test Biweekly 
 Biophysical profile Biweekly 
 USG To assess Gestational Age and Fetal Growth every 2 
weeks 
 Umbilical Artery and Middle cerebral Doppler Biweekly 
CRITERIA TO INTERRUPT EXPECTANT MANAGEMENT AND 
MOVE TO DELIVERY: 
1) MATERNAL INDICATION FOR TERMINATION: 
 Persistent severe Headache 
 Visual Disturbances 
 Eclampsia 
 Shortness of breath with rales,  
SpO2<94% at room air,PULMONARY EDEMA 
 Uncontrolled severe Hypertension inspite of treatment 
 Persistent Platelet count < 1 lakh 
 Oliguria < 500 ml in 24 hours 
 Serum Creatinine ≥ 1.2 mg/dl 
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 Suspected Abruption,progressive labour,or ruptured 
membranes. 
2) FETAL INDICATION FOR TERMINATION: 
 Severe Growth Restriction < 5 percentile for Gestational 
Age 
 Reverse or End Diastolic Flow in Umbilical Artery Doppler 
 Persistent Severe Oligohydramnios(AFI < 5 cm) 
 Biophysical profile ≤ 4 done 6 hours apart 
 Fetal Death. 
MODE OF DELIVERY IN SEVERE PREECLAMPSIA: 
Preferred Mode of Delivery in Preeclampsia is VAGINAL 
DELIVERY. 
Caesarean Section is indicated in cases of 
• Fetal  Distress,Malpresentation 
• Placental Abruption,Placenta Praevia 
• If vaginal delivery cannot be achieved in reasonable time 
usually 24 hours from the decision to induce 
• Or the condition of patient deteriorates. 
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               In case of Severe preeclampsia remote from term ,Caesarean 
section is better than vaginal due to prolonged and unsucessfull induction 
and fetal compromise. 
INTRAPARTUM MANAGEMENT: 
1) Hourly Monitoring of Blood pressure to maintain Systolic BP < 
160 mmHg, Diastolic BP < 110 mmHg with AntiHypertensives. 
2) Hourly Urine Output monitoring 
3) To monitor Signs of Impending Eclampsia, 
4) Eclampsia prophylaxis for those patients with Impending 
Eclampsia  
5) Continuous Fetal Heart Rate Monitoring 
6) Adequate Pain Releif during labour which cut downs 
catecholamine release and Hypertensive response. Epidural 
Analgesia is preferred as it is effective in control of Blood pressure 
and maintaining Cerebral Blood flow38. 
7) If Caesarean section becomes necessary,REGIONAL(EPIDURAL) 
Anaesthesia avoids the risk of aspiration and difficult intubation 
due to airway edema 
8) Do not overload with intravenous fluids 
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9) Third stage should be managed with Oxytocin 10 U im and 10 U in 
drip to  prevent PPH.Ergometrine should not be given as it causes 
intense vasoconstriction that may lead to Hypertensive Crisis. 
ANTIHYPERTENSIVE THERAPY: 
Antihypertensive therapy to a pregnant woman results in exposure 
of fetus to these drugs, hence the potential short term maternal benefits 
have to be balanced against possible short and long term benefits and 
risks to the fetus. There is lack of agreement regarding the blood pressure 
levels at which to initiate AntiHypertensive therapy. But starting 
AntiHypertensive therapy for Systolic BP ≥ 160mmHg or Diastolic BP ≥ 
110mmHg is accepted universally. 
        According to Current Guidelines,AntiHypertensive treatment for            
Non -Severe HTN(140-159/90-109 mmHg) should target to maintain 
systolic BP at 130 – 155 mmHg and Diastolic at 80 – 105 mmHg in a 
woman without any comorbid condition. In those with comorbidities, 
AntiHypertensive drug therapy should be used to keep systolic BP at 130 
– 139 mmHg and Diastolic BP at 80 – 89 mmHg38. 
 FIRST LINE ORAL ANTIHYPERTENSIVE DRUGS:  
 α and β Blocker - Labetalol  
 Centrally Acting- MethylDopa  
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SECOND LINE ORAL ANTIHYPERTENSIVE DRUGS: 
 Calcium channel blocker – Nifedipine 
 BetaBlockers – Metaprolol,Acebutol,propranolol. 
Drugs that are Absolutely Contraindicated in pregnancy are 
Angiotens in Converting Enzymes (ACE Inhibitors) due to its 
teratogenicity. In utero exposure of fetus to these drugs cause growth 
restriction, Oligo, hypotension, anuria, limb contractures. 
A. LABETALOL: 
It has both α and β blocking actions ratio being 1:3 in oral form and 
1:7 in intravenous form. Its becoming first line drug because of its high 
effectiveness, low incidence of side effects. Beta Blockers mainly 
Atenolol is associated with IUGR, Hypoglycaemia, Hyperbiliribinaemia 
in fetus and hence not recommended. 
DOSAGE: 100 to 400mg every 8-12 hours, Maxm Dose = 
1200mg/day. 
SIDE EFFECTS:  
• Bradycardia 
• Hypotension 
• Dizziness 
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• Nausea,Vomiting 
• Insomnia 
• Fatigue 
• Depression 
• Masks the symptoms of Hypoglycaemia in Diabetic patients on 
insulin. 
It is cautiously used in patients of Asthmatics and Heart Failure 
due to its beta blocking action. 
B) ALPHA METHYLDOPA:  
It is a centrally acting Alpha Adrenergic agonist,which acts 
primariliy on Central Nervous System with some effect peripherally to 
stimulate α2 receptors. This Decreases sympathetic tone and Arterial 
Blood Pressure. 
DOSAGE: 250 – 500 mg bd/tds. Maximum Dose upto 2 gms/day. 
Onset of action starts within 4 – 6 hours and persists for 10 – 12 hours. 
SIDE EFFECTS:  
• Postural Hypotension 
• Headache 
• Dryness of mouth 
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• Swelling of feet 
• Depression 
• Rarely Haemolytic anaemia and  
• Drug induced Hepatitis 
It crosses placenta and secreted in Breast Milk,But no 
Teratogenecity reported till now. 
C) CALCIUM CHANNEL BLOCKERS: 
Nifedipine, the calcium channel blocker is the most commonly 
used drug for acute hypertension which is orally effective, easy to 
administer, as well as to store. 
DOSAGE : 10 to 20 mg bd/tds.Maximum dose = 180 mg/day 
ONSET OF ACTION : Within 10 to 15 minutes.Blood pressure is 
monitored every 15 mins and repeat oral dose of 10 mg can be 
administered every 30 to 60 mins until adequate response is achieved. 
ROUTE OF ADMINISTRATION: Oral/sublingual. Oral route is 
preferred because of the precipitous fall in blood pressure with sublingual 
route. 
CAUTION : Nifedipine when used along with magnesium 
sulphate will result in exaggerated hypotension because of their 
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synergistic action in blocking calcium channels.and also there is high 
chance of postpartum haemorrhage. 
SIDE EFFECTS:  
• Headache 
• Dizziness 
• Flushing 
• Palpitation 
• Heartburn 
• Nasal congestion 
• Hypotension 
• Ankle edema 
D)DIURETICS:   
The main indication of diuretics use in pregnancy are as follows: 
• Congestive cardiac failure 
• Acute pulmonary edema 
• Cerebral Intracranial tension 
• Renal failure 
Diuretics causes depletion of intravascular volume which can be 
deleterious in case of preeclampsia which already has a contracted plasma 
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volume. Since the placenta does not have any autoregulatory mechanism, 
placental perfusion is directly linked to the systemic pressure. so the 
reduction of plasma volume will result in reduced uteroplacental flow and 
placental Insufficiency. Hence diuretic use is not recommended in cases 
of preeclampsia with IUGR or Doppler evidence of reduced 
uteroplacental perfusion. 
INTRAVENOUS PREPARATIONS:   
These are used in Hypertensive emergencies with systolic BP > 
160 mmHg, Diastolic BP > 110 mmHg to avoid complications like 
cerebrovascular haemorrhage, cardiac failure, placental abruption, 
eclampsia, Hypertensive encephalopathy. 
A) LABETALOL: 
It lowers the blood pressure  smoothly and rapidly without 
tachycardia, which occurs characteristically in hydralazine. 
DOSAGE : Administered at the dose of 10 to 20 mg intravenous 
initially followed by 20 to 30 mg every 30 mins to the maximum dose of 
300mg. 
Alternatively for continuous IV use,500 mg of labetalol added to 
400 ml of Normal saline and administerd at the initial rate of 20 mg/hour. 
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If the BP does not fall into expected range(systolic < 160/diastolic 80 to 
95 mmHg) in 20 mins,the dose is continued to be doubled every 20 mins 
until expected range is obtained.  
ONSET OF ACTION : Within 5 mins and peak effect within 10 
to 20 mins. 
SIDE EFFECTS : Neonatal Bradycardia, Maternal Hypotension 
and bradycardia. 
B) HYDRALAZINE: 
It acts directly on arteriolar smooth muscle to reduce Peripheral 
vascular resistance. 
It can be given as intermittent bolus of 5 mg intravenously every 
20 to 30 mins or As an infusion at a rate of 0.5 to 10 mg/hour upto maxm 
of 30 mg. 
ONSET OF ACTION :  Within 10 mins 
It initially causes increase in intracranial pressure by dilating the 
capacitance vessels in the cerebral circulation resulting in headache 
which mimics impending eclampsia. subsequently cerebral resistance 
vessels dilates and cerebral vascular flow increases. 
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The sympathetic effect of hydralazine causes marked tachycardia 
due to increased cardiac output. 
SIDE EFFECTS39: 
• Anxiety, Restlessness, Hyperreflexia (mimics impending 
eclampsia) 
• Hypotension 
• Abruption 
• Oliguria 
• Adverse effects on Fetal Heart Rate 
• Low APGAR at 1 min 
Hydralazine releases Nor adrenaline which is a potent 
vasoconstrictor of uteroplacental circulation. Hence continuous fetal heart 
rate monitoring is essential. Abnormal fetal heart rate patterns can be 
prevented by correction of hypovolemia and intermittent use of small 
doses. 
C) SODIUM NITROPRUSSIDE: 
It is a short acting vasodilator of both arterial and venous smooth 
muscle. It is given in Refractory severe Hypertension as an intravenous 
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infusion, started at the rate of 0.25 µg/kg/min and increased to a 
maximum dose of  8 µg/kg/min. 
ONSET OF ACTION : Immediate(< 1 min),Duration of action is 
1 to 3 mins. 
It causes cyanide toxicity to the fetus. 
ECLAMPSIA: 
DEFINITION: 
Development of seizures that cannot be attributed to other causes 
or unexplained coma during pregnancy or puerperium in a woman with 
preeclampsia. It can occur during Antepartum (38-53%), Intrapartum (18-
36%), Postpartum(11-44%),Late postpartum. 
It occurs more common in teenage primi. 
Eclamptic Seizures are self limiting and lasts for 3 to 4 mins.It 
includes 4 stages.    
1) Premonitory stage 
    2) Tonic stage 
    3) Clonic stage 
4) Coma  
42 
 
PATHOPHYSIOLOGY 
Seizures occurs as a result of abnormal autoregulatory response 
which consists of exaggerated vasoconstriction and ischaemic changes 
with rupture of vascular endothelium and pericapillary haemorrhages 
with development of foci of abnormal electrical discharges that 
generalize and cause convulsions.  
Autopsy finding shows cerebral edema, cortical and subcortical 
white matter microinfarcts, pericapillary parenchymal bleeding and 
vascular bleeding in predominantly occipital and watershed areas. 
MATERNAL COMPLICATIONS: 
1) HELLP (9.7 – 20%) 
2) DIC (7 – 11%) 
3) Placental Abruption (7 – 10%) 
4) Acute Renal Failure (5 – 9%) 
5) Pulmonary edema (3 – 5%) 
6) Aspiration Pneumonia (2 – 3%) 
7) Cerebral Haemorrhage, Cardiopulmonary Arrest (2 – 5%). 
Most common cause of maternal death is Intracranial Bleeding and 
Acute Renal failure secondary to placental abruption. 
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FETAL COMPLICATIONS: 
1) Fetal distress 
2) Hypoxic Ischaemic Encephalopathy(HIE) 
3) Intrauterine death. 
Most common cause of perinatal death is due to prematurity and 
Fetal asphyxia. 
MANAGEMENT: It includes, 
1) Control of convulsions 
2) Control of Hypertension 
3) Delivery of fetus 
1) Control of convulsions:  
• CALL FOR HELP,2 IV lines. 
• To put the patient in left lateral position and clearing of airway 
by suctioning to prevent aspiration. 
• Elevate the bedside rails to prevent maternal injury 
• Give O2 by mask @ 8 – 10 L/min 
• Pulse oximeter to monitor  hypoxemia 
• MgSO4 is the drug of choice in treatment of eclampsia. 
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MAGNESIUM SULPHATE:  
It has central anticonvulsant and Neuroprotective effect. 
PRITCHARD’S REGIMEN:  
 Intravenous Loading Dose: Give 20 ml of 20% MgSO4 (4 gm) 
slow i.v for 20 mins. 
 Intramuscular Loading Dose: Give 10 ml of 50% MgSO4 (5 gm) 
deep intramuscular in upper outer quadrant of each buttock using 3 
inch and 20 gauge needle. 
 Maintanence Dose: Give 5 gm of MgSO4 (10 ml of 50% solution) 
deep i.m in alternate buttock every 4 hours. 
 MONITORING FOR MAGNESIUM TOXICITY:  
• Urine output should be atleast 30ml/hour or 100ml in 4 hours. 
• Deep tendon Reflexes should be present 
• Respiratory rate should be > 14/min 
• Pulseoximetry should be ≥ 96% 
MgSO4 is discontinued 24 hours after delivery or after last 
convulsion. 
Therapeutic Range of MgSO4 is 4 – 7 mEq / L. 
First sign of toxicity is loss of patellar reflex. 
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In case of MgSO4 toxicity,give Calcium Gluconate 1gm(10ml of 
10% solution) slow i.v. 
2) CONTROL OF BLOOD PRESSURE: 
           Persistent and severe elevation in blood pressure should be treated 
with parentral antihypertensives to prevent Cerebrovascular accidents, 
Pulmonary edema, and Renal Failure. 
3) DELIVERY OF FETUS: 
The Definitive treatment is Delivery of baby, irrespective of 
gestational age in eclampsia. Patient must Deliver within 24 hours in 
severe preeclampsia and 12 hours in eclampsia. If the patient is stable, 
vaginal examination is done to assess the cervical status, If the cervix is 
favourable, induction of labour / amniotomy and synto acceleration is 
done. If unfavourable cervix, for LSCS. 
  
46 
 
HELLP SYNDROME:  
It is a acronym coined by Louis Weinstein denoting 
1) Haemolysis 
2) Elevated Liver Enzymes 
3) Low Platelets 
It contributes 0.2 – 0.6 % in all pregnancies and 10 – 20 % in 
severe preeclampsia. 
CRITERIA FOR DIAGNOSIS OF HELLP SYNDROME: 
1) HAEMOLYSIS:  
 Abnormal peripheral blood smear(Burr cells,schistocytes) 
 Elevated Bilirubin > 1.2 mg/dl 
 Low serum Haptoglobin 
 Increased LDH(Twice the upper limit of normal >600U/L) 
2) ELEVATED LIVER ENZYMES: 
 Elevated AST and ALT Twice the upper limit of normal(≥ 72U/L) 
3) LOW PLATELET COUNT: 
 Platelet < 1,00,000/mm3 
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MISSISIPPI CLASSIFICATION40: 
1) CLASS I (Severe thrombocytopenia) = Platelet count < 50,000 
2) CLASS II(Moderate thrombocytopenia) = Platelet count 50,000 to 
1,00,000 
3) CLASS III(Mild thrombocytopenia) = Platelet count 1,00,000 to 
1,50,000 
TENNESSEE CLASSIFICATION: 
1) Complete HELLP = All 3 parameters are abnormal. 
2) Incomplete/Partial HELLP = When 1 or 2 parameters are abnormal. 
DIFFERENTIAL DIAGNOSIS: It  needs consideration for 
• Acute Fatty Liver Of Pregnancy 
• Thrombotic Thrombocytopenic Purpura 
• Haemolytic uraemic syndrome 
MATERNAL MORBIDITY IN HELLP SYNDROME: 
 Abruptio Placenta => 10 -15% 
 DIC = >10 – 15% 
 Subcapsular liver haematoma 
 Hepatic rupture(Severe complication) 
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 Pulmonary edema => 6-8% 
 Acute Renal Failure => 5-8% 
 ARDS => 1-2% 
 Death = >1% 
Women with history of HELLP syndrome carry an increased risk 
of 20% in developing some form of Gestational Hypertension in 
subsequent pregnancy41. 
MANAGEMENT OF HELLP: 
        Termination of pregnancy is the treatment of choice.  When 
Gestational age is > 34 weeks => Stabilise the condition and deliver the 
baby. When Gestational age is between 27 – 34 weeks => Antenatal 
steroids for fetal maturity and delivery. The potential benefits has to be 
weighed against the risks of expectant management which include 
abruptio placenta, acute renal failure, pulmonary edema, DIC, perinatal 
and maternal death. 
High dose Corticosteroids has been proposed to improve maternal 
prognosis of HELLP. In recent COCHRANE review, comparing 
corticosteroids with placebo, there was no difference in the risk of 
maternal death. The only clear effect on individual was improved platelet 
count. 
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Follow up is done with measurement of Platelet count and LDH, 
which becomes normal 72 hours following delivery. Other treatment 
modalities includes Platelet transfusion, plasmapheresis. 
LACTIC ACID DEHYDROGENASE: 
Lactate Dehydrogenase (LDH) is mainly an intracellular enzyme 
Which is responsible for interconversion of pyruvate and lactate in the 
cells. LDH levels are several times greater inside the cells than in the 
plasma. So its levels are increased in situations of increased cell 
leakiness, hemolysis and cell death.Preeclampsia is a multisystem 
disorder that leads to a lot of cellular death. So, serum LDH levels can be 
used to assess the extent of cellular death and thereby the severity of 
disease42.Serum LDH Levels can  further be used to help in making 
decision, regarding the management strategies to improve the maternal 
and fetal outcome. 
              Lactate dehydrogenase catalyzes the interconversion of pyruvate 
and lactate with concomitant interconversion of NADH and NAD+. It 
converts pyruvate, the final product of glycolysis, to lactate when oxygen 
is absent or in short supply, and it performs the reverse reaction during 
the Cori cycle in the liver. At high concentrations of lactate, the enzyme 
exhibits feedback inhibition, and the rate of conversion of pyruvate to 
 lactate is decreased. It also catalyses
Hydroxybutyrate, but it is a much poorer substrate than lactate.         
 
 
ISOENZYMES IN MAMMALS:
           Lactate dehydrogenase is composed of four subunits (tetramer). 
The two most common subunits are the LDH
encoded by the LDHA
can form five possible tetramers 
mixed tetramers (3H1M, 2H2M, 1H3M). These five isoforms are 
enzymatically similar but show
electrophretic mobility.
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 The major isoenzymes of skeletal muscle and liver, M4, has four 
muscle (M) subunits, while H4 is the main isoenzymes for heart muscle in 
most species, containing four heart (H) subunits. 
• LDH-1 (4H)—in the heart and in RBC (red blood cells), as well as 
the brain. 
• LDH-2 (3H1M)—in the reticuloendothelial system 
• LDH-3 (2H2M)—in the lungs 
• LDH-4 (1H3M)—in the kidneys, placenta, and pancreas 
• LDH-5 (4M)—in the liver and striated muscle. 
Usually LDH-2 is the predominant form in the serum. A LDH-1 
level higher than the LDH-2 level (a "flipped pattern") suggests 
myocardial infarction(damage to heart tissues releases heart LDH, which 
is rich in LDH-1, into the bloodstream). 
PREECLAMPSIA RESULTS IN INCREASE IN TOTAL LDH. 
NORMAL VALUES OF LDH: 
• Non pregnant adult = 115 – 211 IU/L 
• First Trimester = 78 – 433 IU/L 
• Second Trimester = 80 – 447 IU/L 
• Third Trimester = 82 – 524 IU/L 
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CONDITIONS CAUSING LDH ELEVATION ARE AS FOLLOWS: 
PHYSIOLOGICAL: 
 Strenuous Exercise 
 Pregnancy 
PATHOLOGICAL: 
 Myocardial Infarction 
 Leukemia 
 Haemolysis 
 Muscular Dystrophy 
 Hepatitis 
 Pancreatitis 
STUDIES BASED ON LDH IN PREGNANCY: 
1) A prospective study conducted at 2002, by Qublan et al At King 
Hussein Medical Centre Jordan, 111 preeclampsia women (29 with 
mild and 62 with severe preeclampsia) and 60 normotensive 
controls were studied and  demonstrated a significant association of 
serum LDH levels with severe preeclampsia. Increase in the 
incidence of neonatal deaths was observed in patients with 
increasing levels of serum LDH levels. IUD was seen in 4.8% of 
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cases, IUGR in 33.9% and premature in 77.9%. Neonatal deaths 
were reported in 95.2% patients with severe preeclampsia. 
Severely pre-eclamptic women with LDH levelsof >800 IU/l 
showed a significant increase in complications 
2) A study done in 2008 by Rubin Aziz et al at Karachi ; 100  
pregnant women with 50 as normal pregnant women as control and 
50 preeclampsia women as study group , found that mean serum 
LDH was significantly higher in preeclampsia patients &thereby 
concluded that preeclampsia is characterized by vascular 
endothelial dysfunction & Higher levels Serum LDH can be a 
useful marker to identify the occurrence of complications of 
preeclampsia in early pregnancy which may reduce the risk of 
occurrence of disease.  
3) A prospective comparative study conducted in 2008-09 & 
published in 2011 by Jaiswar S.P et al at Lucknow for 1 year. Total 
146 patients were studied, out of which 26.7% were normal 
pregnant women which served as control group; remaining 73.3% 
cases included pregnancy with eclampsia and preeclampsia. Out of 
these 107 cases 32.7% were mild Out of these 107 cases 32.7% 
were mild preeclampsia, 33.6% were severe preeclampsia and 
33.6% cases were of eclampsia clearly observed that there is 
significant rise in the LDH levels with increasing severity of the 
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disease. The occurrence of neonatal complications, stillbirths and 
perinatal deaths were significantly higher in mothers who had 
increased serum levels of LDH. 
 
URIC ACID: 
Uric acid is the end product formed from Metabolism of Purines.  
Its level is elevated in preeclampsia due to its decreased renal 
clearance or by its increased production by breakdown of purines in 
placenta. Decreased renal clearance is due to altered renal tubular 
function. 
This uric acid impairs the generation of Nitric Oxide from 
endothelial cells causing endothelial cell dysfunction which is the main 
pathophysiology in  Preeclampsia. Hence it is used as the predictive 
marker for Preeclampsia. Various studies have been done on Uric acid 
levels in Preeclamptic patients and correlation with severity of disease, 
maternal and fetal complications. Some studies are as follows. 
1) A Study was done by Disha et al at Civil Hospital,Ahemadabad in 
2012 where 80 Hypertensive women were selectedrandomly and 
retrospectively studied.Birth weight,Gestational age at 
delivery,Complications like HELLP,Eclampsia,IUD,abnormality in 
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platelet count,creatinine,bilirubin were noted.Group were divided 
into 2 based on uric acid levels as <6 and >6mg% and all variables 
correlated.In this study, increase in maternal,fetal 
complications(p<0.05) were noted in group with uric acid 
>6mg%.Mean gestational age at delivery and mean birth weight 
were reduced in group with uric acid>6mg%’ 
2) A prospective study conducted in department of 
O&G,ESIMC,PGIMSR Bangalore from Jan to Aug 2014 in which  
80 pregnant women were included(mild and severe PIH).Uric acid 
and LDH were estimated. The women were followed up till delivery 
and early postpartum. Gestational age at delivery, birth weight, 
mode of delivery, maternal and fetal complications were noted. 
Significant association was found between LDH and uric acid with 
severity of preeclampsia, maternal morbidity, birth weight of babies. 
Gestational age at delivery and neonatal outcome was not 
statistically significant in this study.  
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MATERIALS AND METHODS 
STUDY DESIGN: 
Observational Study 
METHODOLOGY: 
This study involves estimation of serum LDH and Uric acid  in 
normotensive and Hypertensive Antenatal woman in third trimester 
attending Antenatal OPD and Labour ward at Govt R.S.R.M Lying in 
Hospital, Stanley Medical College, during the period of January 2015 to 
September 2015.Patients were selected based on Inclusion and Exclusion 
Criteria. After obtaining their consent, detailed history, clinical 
examination and necessary investigations done accordingly. 
 The study population is divided into  
1) CONTROLS  = 50 
2) SUBJECTS = 115 
SUBJECTS are further subdivided into 3 groups based on Blood  
Pressure  as Mild, Severe Preeclampsia and Eclampsia according to 
NHBPEP Classification. 
 1) MILD PREECLAMPSIA: Blood Pressure of  ≥140/90 to 
<160/110mmHg 
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 2) SEVERE PREECLAMPSIA: Blood Pressure of ≥160/110 
mmHg 
 3) ECLAMPSIA: Preeclamptic patients with 1 or more episode of 
Generalised Tonic Clonic Seizures. 
Study Population is also divided according to LDH and Uric Acid 
Levels as follows:  
 According to Serum LDH levels: 
                       A) <600 IU/L 
                       B) 600 – 800 IU/L 
                       C) >800 IV/L 
 According to serum Uric Acid levels: 
A) <6 mg 
B) >6mg 
Patients were followed till delivery and early postpartum. Maternal 
complications like Abruption, HELLP, Eclampsia, Pulmonary edema, 
Intracranial haemorrhage, Maternal death and Fetal complications like 
IUD, IUGR were noted and correlated with serum LDH and Uric acid 
values. 
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INCLUSION CRITERIA: 
         All Normotensive and Hypertensive Antenatal woman in third 
trimester. 
EXCLUSION CRITERIA: 
1) Mothers with Hypertension < 20 weeks of gestation(Chronic  
 Hypertension) 
2) Preexisting Diabetes Mellitus 
3) Liver disorder 
4) Renal disorder 
5) Epilepsy 
6)Thyroid disorder 
7) Heart Disease 
8) Leukemia 
9) Haemolysis 
10) Hepatitis 
11) Pancreatitis 
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METHOD OF LDH ESTIMATION: 
Under aseptic precautions, 1 ml venous blood taken. 
Sample allowed to clot and then centrifuged for serum to be separated. 
By International FederationOf Clinical Chemistry(IFCC) method, 
estimation of serum LDH done. 
PRINCIPLE: 
Reduction of pyruvate with NADH forms NAD.This reaction is 
catalysed by Lactate Dehydrogenase.Temperature for this reaction to 
occur is of 30±0.050C and pH of 9.40±0.05. 
340 nm is the absorbance maximum for NADH, Which after a period 
of time,it is used up and there is decrease in absorbance which is 
proportional to the enzyme activity that is detected by spectrophotometer. 
SAMPLE MATERIAL: 
The sample should be serum that is free from haemolyis. Total 
LDH is found to be stable in serum at 2 – 8oC for about 1 – 3 days. 
Freezing causes inactivation of Liver isoenzyme. 
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PROCEDURE: 
Under 300C at 340nm=> First,Substrate start Assay is done by 
adding the sample to Buffer and Starter reagent, initial absorbance is 
noted and absorbance values are noted every 1,2,3 mins.Mean 
Absorbance change/min is calculated. Then Sample start Assay is done 
by adding working reagent to sample and Mean Absorbance Change/min(     
A/min)  is calculated. 
CALCULATION:   
LDH Activity in U/L (30oC) =      A / min   X 3333 
ESTIMATION OF SERUM URIC ACID: 
Uric acid is the catabolite formed from Purine Metabolism. 
Uric acid estimation can be done by 2 methods. 
1) Colorimetric Method(Phototungstic method) or 
2)  Enzymatic method(Uricase Method). 
Enzymatic method is the most commoly used method. It involves  
oxidation of uric acid by uricase enzyme which convert the substrate to 
Allantoin. It is Quantified based on Differential Absorbance at 293 nm 
for these substances. 
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OBSERVATION AND RESULTS 
A total of 165 Antenatal women attending OPD / Labour ward at 
Stanley Medical College from January 2015 to September 2015 were 
included in the study. 
             Study population were taken from third trimester. Both  
Normotensives and Hypertensives were included. They were selected 
irrespective of age, parity. Based on NHBPEP Classification, The study 
had 4 separate groups , one being a normotensive control with 50 women, 
and the rest three being patients with mild pre-eclampsia, severe pre-
eclampsia and eclampsia amounting to 48, 53 and 14 respectively. 
Patients were divided further according to serum LDH values as < 600, 
600 – 800, > 800 IU/L and based on serum uric acid values as < 6 mg and 
> 6 mg%. LDH and Uric Acid values were compared with Maternal and 
Fetal outcomes and studied using appropriate statistical test. 
The results were compared based on One Way Analysis of 
Variance, chi-square test and differences were considered as significant 
when p<0.05. 
The observations and results from this study are as follows. 
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AGE DISTRIBUTION AMONG GROUPS 
In our study, age distribution among study population which 
included 11 patients (6.7%) of age <19 years,110 patients(66.7%) from 
20-25 years, 30 patients(18.2%) from 26-30 yrs and 14 patients(8.5%) of 
> 30 yrs                          
 
Out of 11 patients in age <19 years,3(27.3%) belong to mild 
preeclampsia,3(27.3%) belong to severe preeclampsia,5(45.5%) belong to 
Eclampsia, and none of the patients in normotensive group. Among 20-25 
yrs age group,37(33.6%) are normotensives,28(25.5%) belong to mild 
preeclampsia,37(33.6%) belong to severe preeclampsia and 8(7.3%) 
belong to eclampsia. Among 26-30 yrs age group,9(30%) belong to 
controls,13(43.3%) belong to mild preeclampsia,7(23.3%) belong to 
Age in 
years 
 
<= 19 
 
20-25 
 
26-30 
 
> 30 
 Group 
 
Control 
Mild 
Preeclampsia 
Severe 
Preeclam
psia 
Eclampsia 
% within Age in 
years 
.0% 27.3% 27.3% 45.5% 
% within Age in 
years 
33.6% 25.5% 33.6% 7.3% 
% within Age in 
years 
30.0% 43.3% 23.3% 3.3% 
% within Age in 
years 
28.6% 28.6% 42.9% .0% 
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severe preeclampsia and 1(3.3%)patient in eclampsia group. Among age 
>30 years,4(28.6%) belong to controls,4(28.6%) belong to mild 
preeclampsia,6(42.9%) in severe preeclampsia and none of the patients in 
Eclampsia. 
In Extremes of age group(<19yrs &>30 yrs) higher percentage 
of individuals belong to severe preeclampsia and eclampsia. 
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DISTRIBUTION OF PARITY AMONG STUDY POPULATION: 
             Out of 165 patients, 91(55.2%) are primigravida,59(35.8%) were 
G2,11(6.7%) are G3,4(2.4%) are G4 and above. High percentage of 
patients were Primi group. 
DISTRIBUTION OF PARITY AMONG CASES:         
 
Out of 165 women in study group,91 patients are primigravida,and 
74 are G2 and above. Parity distribution among different groups were 
analysed by chisquare test and the P Value is 0.18. There is no 
statistically significant difference in distribution of parity among 
groups. 
  
Obstetrics 
Score 
 
Primi 
 
 
G2 
 
 
G3 
 
G4 and above 
 
 Group  
 
 
 
 
 
 
 
 
P 
Value<
0.187 
 Control 
Mild 
Preeclampsia 
Severe 
Preeclampsia Eclampsia 
% within 
Obstetrics 
Score 
24.2% 30.8% 34.1% 11.0% 
% within 
Obstetrics 
Score 
42.4% 25.4% 25.4% 6.8% 
% within 
Obstetrics 
Score 
18.2% 45.5% 36.4% .0% 
% within 
Obstetrics 
Score 
25.0% .0% 75.0% .0% 
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LDH AMONG DIFFERENT GROUPS: 
 
 
 
92.9% of the patients who had eclampsia had higher LDH levels 
more than 800 U/L; levels were equally split up in the 3 LDH ranges in 
patients with severe pre-eclampsia (p<0.001). However normal patients 
or those with mild pre-eclampsia had LDH levels <600 IU/L. 
 
Group
Eclampsia
Severe Preeclampsia
Mild Preeclampsia
Control
Co
u
n
t
60
50
40
30
20
10
0
LDH
< 600
600-800
> 800
Group % patients with 
LDH <600 U/L 
% patients with 
LDH 600-800 
% patients with 
LDH >800 U/L 
P value 
Control 95 2 0  
 
 
< 0.001 
Mild pre-
eclampsia 
83.3 16.7 0 
Severe pre-
eclampsia 
34 32.1 34 
Eclampsia 0 7.1 92.9 
P Value<0.001 
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ASSOCIATION BETWEEN LDH AND SYSTOLIC BP: 
 
 
       Among 107 patients with LDH<600 IU/L, majority (47.7%) were 
normotensive. Among 27 patients with LDH 600-800IU/L, 51.9% had 
SBP 160 and above. Out of 31 patients with LDH>800IU/L, none were 
normotensive, and 98.8% had SBP 160 and above (p<0.001).Serum 
LDH and Systolic BP found to have significant association. 
 
 
 
SBP
160 and above140-15990-139
Co
u
n
t
60
50
40
30
20
10
0
LDH
< 600
600-800
> 800
P value<0.001 
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ASSOCIATION BETWEEN LDH AND DIASTOLIC BLOOD 
PRESSURE: 
 
Out of 107 patients with LDH <600IU/L, 44.9 had normal 
Diastolic BP. Out of 27 patients with LDH 600-800IU/L, 
majority(59.3%) had DBP 110 and above. Out of 31 patients with 
LDH>800IU/L, 93.5 had DBP 110 and above (P Value <0.001).There 
was significant Association between serum LDH and DBP. 
  
DBP
110 and above90-10960-89
Co
u
n
t
60
50
40
30
20
10
0
LDH
< 600
600-800
> 800
P Value<0.001 
68 
 
ASSOCIATION BETWEEN LDH AND PROTEINURIA: 
 
34 patients without proteinuria had LDH<600IU/L and 94% of 
trace excretion had LDH<600.  
Out of 49 patients with 1+ proteinuria, majority (81.6% had LDH 
<600 IU/L.  
Out of 34 patients with 2+ oteinuria,14(41%),10(29%),10(29%) 
had LDH <600, 600-800,>800 IU/L respectively. 
Among 24 patients with 3+ proteinuria,4(17%),7(29%),13(54%) 
had LDH <600,600-800,>800 IU/L respectively. Out of 8 patients with 
4+ proteinuria, none had LDH<600 and 87% had LDH >800IU/L 
(p<0.001).Increasing LDH values isassociated with increasing 
severity of proteinuria. 
Urine Albumin
4+3+2+1+TraceNil
Co
u
n
t
50
40
30
20
10
0
LDH
< 600
600-800
> 800
P Value<0.001 
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SERUM LDH AND GESTATIONALAGE IN WEEKS: 
Group 
% patients 
with LDH 
<600 U/L 
% patients 
with LDH 
600-800 
% patients 
with LDH 
>800 U/L 
P value 
<34 0.9 3.7 6.6  
P < 0.05 34-36 7.6 33.3 58.1 
>36 91.6 63 35.6 
 
       Among 107 patients with LDH<600IU/L,0.9 % delivered at <34 
weeks,8% delivered between 34-36 weeks,92% delivered at >36 weeks. 
Among 27 patients with LDH 600-800IU/L, 3.7%,33%,63% delivered at 
<34, 34-36,>36 weeks respectively. Among 31 patients with 
LDH>800IU/L, 6.6%, 58%, 35.6% delivered at <34, 34-36,>36 weeks 
respectively. There is significant difference in Gestational age of delivery 
between each groups. There was a reduction inmean gestational age 
with increase in LDH. Propably due to more pretermdeliveries. 
SERUM LDH AND MODE OF DELIVERY: 
There was no statistical difference between the mode of delivery 
and serum LDH values. But there is higher percentage of Operative 
deliveries(LSCS) in all groups ,that is more significant in groups with 
LDH 600-800 and >800IU/L. 
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SERUM LDH AND BIRTH WEIGHT : 
 
         Out of 107 patients with LDH<600 IU/L,61% of babies had birth 
weght>2.5kg,39% had birth weight 2-2.5kg,2.8% had birth weight<2 kg. 
Out of 27 patients with LDH 600-800 IU/L,22%,37%,41% had birth 
weight >2.5kg, 
2-2.5kg,<2kg respectively. Among patients with 
LDH>800IU/L,68% of babies had birth weight<2kg,32% of babies had 
birth weight between 2-2.5kg and none of the babies had birth weight 
>2.5kg. There is Significant Association between LDH and birth 
weight of baby. With Higher values of LDH, there was significant 
reduction in the birth weight (p<0.001). 
Baby weight in kg
> 2.52.0-2.5< 2
Co
u
n
t
70
60
50
40
30
20
10
0
LDH
< 600
600-800
> 800
P Value<0.001 
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ASSOCIATION OF LDH WITH MATERNAL AND FETAL 
COMPLICATIONS: 
         The levels of LDH were compared with various maternal and fetal 
complications as depicted in table below. 
Complications 
patients with 
LDH <600 
U/L 
patients with 
LDH 600-800 
Patients with 
LDH >800 
U/L 
P value 
IUD 1 4 4 0.001 
IUGR 1 10 23 0.001 
Intra cranial hge 0 0 1 NS 
Pulmonary edema 0 1 0 NS 
HELLP 0 1 4 0.02 
Abruption 4 9 6 0.001 
Eclampsia 0 1 13 0.001 
Maternal death 0 0 1 NS 
 
There was a higher number of IUDs and infants with IUGR who 
were born to mothers who had LDH levels > 800 IU/L(p=0.001). Among 
the maternal complications, 1 mother had intra cranial haemorrhage 
(>800IU/L), 1 had pulmonary edema (600-800IU/L), 1 mother died post 
partum(>800IU/L) due to intra cranial hemorrhage (p NS). However, 
patients with  abruption(15/19) had LDH more than 600 IU/L and 
majority of patients with HELLP(4/5) and eclampsia(13/14) had LDH 
more than 800IU/L. 
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URIC ACID LEVELS AMONG STUDY GROUPS: 
 
 
Group
Eclampsia
Severe Preeclampsia
Mild Preeclampsia
Control
Co
u
n
t
60
50
40
30
20
10
0
Uric Acid
< 6
> 6
Group 
% of patients with 
uric acid <6mg 
% patients with 
uric acid >6mg 
P value 
Control 100 0  
 
 
< 0.001 
Mild pre-
eclampsia 
70.8 29.2 
Severe pre-
eclampsia 
11.3 88.7 
Eclampsia 7.1 92.9 
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In control and mild preeclampsia group,100% and 71% 
respectively had uric acid <6mg .89% of severe preeclamptic women had 
uric acid>6mg and 92% of the Eclamptic women had uric acid>6mg. 
There was Statistically significant association of serum uric acid and 
severity of preeclampsia(P value <0.001) 
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ASSOCIATION BETWEEN SERUM URIC ACID AND 
GESTATIONAL AGE AT DELIVERY: 
Group 
% patients with 
Uric acid<6mg 
% patients with 
Uric acid>6mg 
P value 
<34 25 75  
P < 0.05 34-36 17.1 82.9 
>36 66.7 33.3 
 
 
As depicted in the diagram above, Occurrence  of preterm delivery 
is more common in women with serum uric acid >6mg% probably due to 
earlier termination of pregnancies in view of preeclampsia. 
  
Gestational age in weeks
>= 3734-36.6< 34
Co
u
n
t
100
80
60
40
20
0
Uric Acid
< 6
> 6
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ASSOCIATION BETWEEN SERUM URIC ACID AND 
PROTEINURIA: 
 
 
          As depicted in the diagram above, Increasing Proteinuria is 
significantly associated with Higher uric acid levels(P value <0.05) 
  
Urine Albumin
4+3+2+1+TraceNil
Co
u
n
t
40
30
20
10
0
Uric Acid
< 6
> 6
P value  <0.05 
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ASSOCIATION OF SERUM URIC ACID AND SYSTOLIC BP: 
Systolic BP 
mmHg 
% patients with 
Uric acid<6mg 
% patients with 
Uric acid>6mg 
P value 
90-139 94.4 5.6  
P < 0.001 140-159 62 38 
160 and above 14.8% 85.2% 
 
 
          As shown in the table above,Majority(85.2%) of the patients with 
systolic BP of >160mmHg had uric acid levels>6mg.(P Value<0.001) 
 
SBP
160 and above140-15990-139
Co
u
n
t
60
50
40
30
20
10
0
Uric Acid
< 6
> 6
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ASSOCIATION OF URIC ACID WITH DIASTOLIC BP: 
Diastolic BP 
mmHg 
% patients with 
Uric acid<6mg 
% patients with 
Uric acid>6mg 
P value 
60-89 100 0 
 
P < 0.001 
90-109 62.5 37.5 
110 and above 11.7% 88.3% 
 
         88.3% of the patients with DBP >110mmHg had uric acid levels 
>6mg but not so in those patients with DBP <90mmHg.(P value <0.001). 
ASSOCIATION OF URIC ACID WITH BIRTH WEIGHT: 
Birth weight in 
Kg 
% patients with 
Uric acid<6mg 
% patients with 
Uric acid>6mg 
P value 
<2 8.6 91.4 
 
P < 0.001 
2-2.5 52.5 47.5 
>2.5 80.3 19.7% 
 
          As depicted in the table above, 91% of the babies with birth weight 
<2Kg were born to mothers who had uric acid levels >6mg%. 
(P value<0.001). 
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ASSOCIATION OF URIC ACID WITH MATERNAL AND FETAL 
COMPLICATIONS 
 
          There was a higher number of IUDs and infants with IUGR who 
were born to mothers who had uric acid >6 mg%(p=0.001). Among the 
maternal complications, 1 mother had intra cranial haemorrhage >6 
mg%)), 1 had pulmonary edema (>6mg%), 1 mother died post 
partum(>6mg%)) due to intra cranial hemorrhage (p NS). However, 
patients with abruption(15/19) had uric acid more than 6 mg% and 
majority of patients with eclampsia(13/14) and all patients with HELLP 
had LDH more than 6 mg%. 
 
Complications 
Uric acid 
<6mg% 
Uric acid 
>6mg% 
P value 
IUD 1 8 0.007 
IUGR 3 31 0.001 
ICH 0 1 NS 
Pulmonary 
edema 
0 1 NS 
HELLP 0 5 0.02 
Abruption 4 15 0.002 
Eclampsia 1 13 0.01 
Maternal death 0 1 NS 
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ASSOCIATION BETWEEN LDH AND URIC ACID: 
As both LDH and uric acid had similar associations with th 
parameters assessed, a comparison was done between LDH and uric acid. 
As in the table, majority of patients(40.5%) who had LDH >800 IU/L 
also had high uric acid levels >6 mg% which was statistically significant 
(p<0.001) 
 
 
 
 
 
 
Group 
% patients 
with LDH 
<600 U/L 
% patients 
with LDH 
600-800 
% patients 
with LDH 
>800 U/L 
P value 
Uric acid 
<6mg% 
95.6 3.3 1.1 
 
< 0.001 Uric acid > 
6mg% 
27 32.4 40.5 
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DISCUSSION 
Our study was conducted in the Department of Obstetrics and  
Gynecology, RSRM Hospital, Stanley Medical College.  A total of 165 
antenatal women were recruited from Outpatient department/ Labour 
Ward at Stanley Medical College & Hospital  from Jan2015 - September 
2015 All patients were of gestational age 28 weeks and above.  
Patients were selected based on the inclusion and exclusion criteria 
irrespective of the age and parity and they were divided into three groups 
based on NHBPEP classification as 50 normotensives, 48 mild pre-
eclamptics, 53 severe pre-eclamptics & 14 eclamptics. Patients were also 
divided into three groups based on their S. LDH (less than 600, 600 to 
800, and more than 800 IU/l) and two groups based on uric acid levels 
(<6mg% and >6mg%) 
All the diagnostic components and the possible maternal and fetal  
complications of pre-eclampsia were compared with their LDH and uric 
acid levels. 
This study was similar to the study done by S.P Jaiswar et al and 
Disha et al.  
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Discussion on LDH : 
The distribution of age & mean age between LDH groups were 
almost similar. No significant difference was observed in terms of parity 
between groups and moreover they did not influence S.LDH in contrast to 
Qublan et al and Jaiswar et al. Qublan et al stated that the majority were 
young primigravida in the affected population.  
S. LDH levels consistently increased with increasing systolic & 
diastolic blood pressure, with a P value of <0.001 similar to Jaiswar & 
Amrit et al (p=0.01).  
Most of the women with severe preeclampsia & eclampsia had  
severe proteinuria and S. LDH significantly increased with the severity of 
proteinuria (P<0.001). Results were comparable to Qublan et al who 
showed a significant increase in S. LDH with severity of proteinuria 
(P value of <0.05).  
In the study done by S.P.Jaiswar et al, only 1 case had abruptio 
Placenta and 1 had HELLP but the incidence was  high with 19 cases of 
abruption and 5 cases of HELLP in this study.LDH levels were 
significantly elevated in patients with these maternal complications(P 
<0.001) which was comparable to Jaiswar et al who showed significant 
increase in maternal morbidity with the increasing LDH levels  
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1 maternal death occurred in the study population and had LDH 
levels more than 800IU/L and died of intra cranial haemorrhage.   
Higher LDH levels were associated with increased number of pre-
term deliveries probably because of the severity of pre-eclampsia. 
The incidence of operative delivery was elevated with increased 
LDH levels though did not reach statistical significance. 
Women with LDH <600 IU/L  gave birth to babies with adequate 
birth weight more than 2.5 kg. However those who had >800IU/L had 
LBW <2kg (p<0.001) 
This fact could be explained by the increased preterm deliveries 
and the need for early termination of pregnancy to improve the maternal 
outcome in view of severity of disease.   
Complications like growth restriction & late intrauterine fetal 
demise are well known complication of pre-eclampsia. He S , Bremme K, 
Kallner et al studied the S. LDH levels in pre-eclamptic women with 
small for gestational age infants and found a significant correlation 
between both. Incidence of IUGR and IUD were significantly higher in 
pre-eclamptic women and their S. LDH levels compared to the controls 
were abnormally high (P value < 0.00) similar to He. S et al.   
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Discussion on uric acid  : 
S. uric acid levels consistently increased with increasing systolic & 
diastolic blood pressure, with a P value of <0.001. The results of our 
study were similar to the study by Roberts et al, wherein uric acid was 
elevated in 75% of patients with diagnosed PIH. 
Most of the women with severe preeclampsia & eclampsia had 
severe proteinuria and uric acid levels significantly increased with the 
severity of proteinuria (P<0.001) similar Hawkin’s et al where 59% 0f 
patients with proteinuria had high uric acid levels. 
1 maternal death occurred in the study population and had uric acid 
more than 6mg% which is similar to the results of Patel et al where there 
was only 1 maternal mortality in patients with high uric acid levels >6 
mg%  
Higher uric acid were associated with increased number of pre-
term deliveries probably because of the severity of pre-eclampsia, the 
results of which was similar to that of Disha et al, where there were more 
number of patients high uric acid  who were delivered pre term than with 
low uric acid levels.  
The incidence of operative delivery was elevated with increased 
uric acid levels (p=0.02) probably due to the severity of the disease. 
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Patients with Uric acid <6mg%  gave birth to babies with adequate 
birth weight more than 2.5 kg. However those who had >6mg%had LBW 
<2.5kg (p<0.001), results being similar to that of Disha et al where 17/23 
children who had BW < 2kg were born to mothers who had high uric acid 
levels (>6.5 mg%)  
This fact could be explained by the increased preterm deliveries 
and the need for early termination of pregnancy to improve the maternal 
outcome in view of severity of disease.   
Our study reported 9 IUD, of which 8 had uric acid levels more 
than 6mg%. Similar study done by Patel et al, showed similar results 
where all 8 IUD was associated with uric acid levels > 6 mg% . 
19 cases of abruption were reported in our study among which 15 
cases had uric acid levels>6mg%(p value<0.001),similar study done by 
disha et al were 3 out of 4 cases of abruptio placenta had uric 
acid>6mg%. 
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SUMMARY 
Ours was a comparative observational study done on 165 patients 
attending Outpatient department/ Labour Ward at Stanley Medical 
College & Hospital from Jan 2015 - September 2015 Our study was done 
in search of a valuable marker for preeclampsia and Eclampsia which 
would reflect the severity of the disease and would predict the maternal 
and fetal outcome so that such markers can help in decision making and 
can influence the current management protocols in order to achieve a 
better maternal and perinatal outcome. Lactate dehydrogenase and uric 
acid has been suggested by various authors as a promising marker and the 
inferences made out of this study are as follows.  
1. Extremes of age was associated with elevated LDH but not uric 
acid  
2. Parity does not affect the levels of either LDH or uric acid 
3. Patients with high S. LDH and uric acid levels also had high SBP 
and DBP(p<0.001) 
4. Proteinuria by itself is a marker of severity of the disease and was 
associated with high LDH and uric acid (p<0.001), hence LDH and 
uric acid, may be used as similar markers with high significance 
and hence the need for management strategies based on S. LDH 
and uric acid. 
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5. Patients with elevated LDH and uric acid had increased numbers of 
pre-term deliveries especially between 34-36 weeks 
6. High uric acid levels was associated with increased chances of 
operative deliveries probably to reduce maternal or fetal morbidity 
and mortality 
7. High LDH and uric acid levels were associated with low birth 
weight less than 2 kg, probably as a result of increased risk of 
IUGR and pre-term deliveries 
8. High uric acid and LDH levels were significantly associated with 
more number of IUDs 
9. High uric acid and LDH levels were associated with high chances 
of abruption, HELLP, eclampsia. 
10. Though rare complications like pulmonary edema, intracranial 
haemorrhage and maternal deaths were associated with high LDH 
and uric acid levels, it did not reach statistical significance. 
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CONCLUSION 
1. S. LDH and uric acid values were significantly high in pre-
eclamptic patients depending on the severity of the disease 
indicating the increased cellular turnover in them.  
 
2. Higher LDH and uric acid levels was associated with diagnostic 
components of preeclampsia like SBP, DBP, Proteinuria, maternal 
morbities like abruption, HELLP, eclampsia, intracranial 
haemorrhage, pulmonary edema or death and fetal morbidities like 
IUGR or sometimes IUD 
 
3. Hence diagnostic and management strategies may be considered 
based on S.LDH and uric acid levels and further studies on a larger 
sample can be done to substantiate our observations on the utility 
of this parameter as a diagnostic and prognostic component of 
preeclampsia.  
 
4. Development of new management strategies based on S. LDH and 
uric acid levels may help in appropriate decision making thereby 
avoiding unwanted maternal & fetal deaths.   
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 CONSENT FORM 
 
 
 
 
 
I agree to participate in the study entitled "LACTIC ACID 
DEHYDROGENASE AND URIC ACID- BIOCHEMICAL 
MARKERS FOR PRE ECLAMPSIA - ECLAMPSIA" 
 
I confirm that I have been told about this study in my mother  
tongue  and have had the opportunity  to clarify my doubts. 
 
I understand  that my participation   is voluntary  and I may refuse to 
participate  at any time without   giving any reasons  and without  affecting  
my benefits. 
 
I agree not to restrict the use of any data or results that arise from 
this study. 
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1 Victoria 21 8748 Primi Severe Preeclampsia 33 3+ 317 6.2 170 100 LN 1.2  -  -  -      -      -      -      -      -
2 Vijayakumari 21 8846 Primi Severe Preeclampsia 39 2+ 1288 7.3 160 110 Emerg.LSCS 2.05  - 1  -      -      -      -      -      -
3 Dharshini 26 8848 Primi Mild Preeclampsia 40 1+ 209 7 130 100 LN 2.7      -      -  -      -      -      -      -      -
4 Reshma 20 8962 Primi Severe Preeclampsia 40 2+ 234 6.6 140 110 Emerg.LSCS 3.1      -      -  -      -      -      -      -      -
5 Vijayalakshmi 25 9406 G2P1L1 Severe Preeclampsia 36 2+ 554 6.2 160 104 Emerg.Rpt LSCS 2.2  -  -      -      -      -      -      -
6 Saraswathy 32 9524 G3P2L1 Mild Preeclampsia 37 1+ 141 5.8 140 96 Elect.Rpt LSCS 3.2      -      -  -      -      -      -      -      -
7 Sindhumathi 23 2053 G2P1L1 Control 37 nil 128 3.8 120 70 Emerg.Rpt LSCS 2.8      -      -  -      -      -      -      -      -
8 Kalaiarasi 21 9147 Primi Mild Preeclampsia 38 1+ 204 4.8 140 94 Emerg.LSCS 2.6      -      -  -      -      -      -      -      -
9 Shanthi 33 10106 Primi Mild Preeclampsia 39 1+ 378 2.4 140 90 LN 2.5      -      -  -      -      -      -      -      -
10 Alamelu 22 10166 Primi Mild Preeclampsia 40 1+ 456 4.2 140 96 LN 2.4      -      -  -      -      -      -      -      -
11 Nagammal 18 9696 G2A1 Eclampsia 30 1+ 1257 5.1 170 110 Emerg.Hysterotomy 0.95      -      -  -      -      -      - 1      -
12 Sasirekha 24 9994 G2P1L1 Mild Preeclampsia 37 1+ 428 6.2 140 100 Emerg.Rpt LSCS 2.8      -      -  -      -      -      -      -      -
13 Sangeetha 28 10130 G2P1L1 Mild Preeclampsia 36 1+ 660 6.5 150 100 LN 1.8  -  -  -      -      -      -      -      -
14 Ameena 20 10221 G2P1L1 Severe Preeclampsia 38 2+ 750 7.1 160 100 Emerg.Rpt LSCS 2.1  - 1  -      -      -      -      -      -
15 Seethalakshmi 18 10219 G2P1L0 Severe Preeclampsia 37 2+ 580 6.8 150 110 LN 2.3  -  -  -      -      -      -      -      -
16 Sulthana 30 12312 G2P1L1 Mild Preeclampsia 36 1+ 192 5.5 160 100 Emerg.Rpt LSCS 1.9  -  -  -      -      -      -      -      -
17 Nanthini 23 2020 G2P1L1 Control 39 nil 154 3.2 120 70 Emerg.LSCS 3.3  -      -  -      -      -      -      -      -
18 Latha 26 12300 G2P1L1 Severe Preeclampsia 37 2+ 376 6.5 170 110 Emerg.Rpt LSCS 2.7      -      -  -      -      -      -      -      -
19 Vidhya 24 10041 Primi Severe Preeclampsia 36 3+ 1226 6.2 150 110 Emerg.LSCS 1.75 1  -      -      -      -      -      -
20 Preetha 24 12071 G3P2L0 Control 38 Trace214 4 130 74 Emerg.LSCS 3.36      -      -  -      -      -      -      -      -
21 Sivasakthi 19 10420 G2A1 Eclampsia 28 2+ 1450 6.5 170 110 Emerg.LSCS 1.25  -  -      -      -      - 1      -
22 Radhika 24 10091 Primi Severe Preeclampsia 37 2+ 1356 7.2 190 100 Emerg.LSCS 1.8 1  -      -      -      -      -      -
23 Priyadharshini 19 10871 Primi Mild Preeclampsia 38 1+ 440 5.6 140 96 Emerg.LSCS 2.7      -      -  -      -      -      -      -      -
24 Vanitha 17 11132 Primi Mild Preeclampsia 37 1+ 320 5 160 90 Emerg.LSCS 2.6      -      -  -      -      -      -      -      -
25 Sankari 35 12091 G2P1L1 Control 38 nil 156 2.7 130 80 Emerg.Rpt LSCS 3.17      -      -  -      -      -      -      -      -
26 Radhika 30 10247 Primi Mild Preeclampsia 36 1+ 224 7.2 150 100 Emerg.LSCS 2.5      -      -  -      -      -      -      -      -
27 Ramya 20 11275 Primi Severe Preeclampsia 37 3+ 414 6.1 180 100 Emerg.LSCS 2.6      -      -  -      -      -      -      -      -
28 Valli 19 11475 G2P1L0 Severe Preeclampsia 37 2+ 1515 6.5 170 120 Emerg.LSCS 2.2      - 1  -      - 1      -      -
29 Nirmala 36 2082 G2P1L1 Control 39 Trace190 3.2 110 70 Emerg.Rpt LSCS 3.1      -  -      -      -      -      -      -
30 Jayanthi 22 12012 Primi Mild Preeclampsia 39 1+ 215 3.6 140 90 LN 2.8      -      -  -      -      -      -      -      -
31 Sumaiya 23 12057 G2P1L1 Severe Preeclampsia 38 2+ 820 6.3 160 110 LN 2.3  -  -  -  -  -  -  -  -
32 Mala 27 12177 G2P1L1 Mild Preeclampsia 39 1+ 360 5 140 90 Emerg.LSCS 2.8  -  -  -  -  -  -  -  -
33 Pushpam 34 12204 G2P1L1 Mild Preeclampsia 38 1+ 284 4.8 150 94 Emerg.Rpt LSCS 3  -  -  -  -  -  -  -  -
34 Nasilima 22 12279 Primi Eclampsia 37 3+ 820 7.2 180 112 Emerg.LSCS 2.1  - 1  -  -  -  - 1  -
35 Nadhiya 29 7221 G2P1L1 Severe Preeclampsia 38 2+ 770 6.8 160 116 Emerg.LSCS 2.8 1  -  -  -  - 1  -  -
36 Sangeetha 29 12277 G2P1L0 Mild Preeclampsia 37 1+ 288 5.6 150 90 LN 2.5  -  -  -  -  -  -  -  -
37 Ellamal 21 20078 G2P1L1 Control 38 nil 166 2.2 120 70 Emerg.LSCS 3.1  -  -  -  -  -  -  -  -
38 Parveen 33 7807 G2P1L1 Severe Preeclampsia 36 2+ 960 7.4 160 120 Emerg.LSCS 1.9 1  -  -  - 1  -  -
39 Bhavani 19 8001 Primi Severe Preeclampsia 36 2+ 570 5.5 160 112 LN 2.5  -  -  -  -  -  -  -  -
40 Allima 28 2100 G3P2L1 Control 39 trace201 3 110 80 Emerg.Rpt LSCS 3.02  -  -  -  -  -  -  -  -
41 Lillirani 22 9825 G2A1 Mild Preeclampsia 40 1+ 700 6.1 140 108 Emerg.LSCS 3 1  -  -  -  - 1  -  -
42 Jhansi 19 10267 Primi Eclampsia 34 3+ 1376 7.2 190 120 Emerg.LSCS 1.1 1 1  -  -  -  - 1  -
43 Saritha 28 10776 Primi Severe Preeclampsia 36 2+ 1040 6.7 160 110 LN 1.4 1 1  -  -  - 1  -  -
44 Kalpana 28 2099 G2P1L1 Control 38 nil 246 2.8 130 70 Emerg.LSCS 2.6  -  -  -  -  -  -  -  -
45 Kaveri 22 2112 Primi Control 38 Trace224 3.2 120 80 Emerg.LSCS 2  - 1  -  -  -  -  -  -
46 Kalaiselvi 31 11069 G3P2L2 Severe Preeclampsia 34 2+ 700 6.2 180 110 Emerg.Rpt LSCS 1.5 1  -  -  - 1  -  -
47 Vinnarasi 23 11909 G2P1L1 Severe Preeclampsia 38 2+ 766 7.5 170 120 Emerg.Rpt LSCS 3.2 1  -  -  -  - 1  -  -
48 Muthari 23 12015 G2P1L0 Mild Preeclampsia 37 1+ 380 4.1 150 90 Elective LSCS 3  -  -  -  -  -  -  -  -
49 Thilagavathy 23 1245 Primi Severe Preeclampsia 38 3+ 568 6.2 160 112 Emerg.LSCS 2.3  -  -  -  -  -  -  -  -
50 Gomathy 23 2028 G2P1L1 Control 39 nil 146 2.8 120 76 Elective LSCS 2.8  -  -  -  -  -  -  -  -
Emerg.LSCSJayalakshmi 21 2079 G2P1L1 Control 39 Trace610 5 130 80 Elective Rpt LSCS 2.25  - 1  -  -  -  -  -  -
52 Gayathri 24 12554 G2P1L1 Mild Preeclampsia 38 1+ 470 5.1 150 100 Emerg.Rpt LSCS 3.2  -  -  -  -  -  -  -  -
53 Sumalatha 31 12413 G2P1L1 Mild Preeclampsia 37 1+ 520 4.8 150 90 Elective Rpt LSCS 2.6  -  -  -  -  -  -  -  -
54 Poonam 21 12653 Primi Severe Preeclampsia 38 2+ 540 5.8 160 114 Emerg.LSCS 2.75  -  -  -  -  -  -  -  -
55 ParveenBanu 22 11719 Primi Mild Preeclampsia 37 1+ 514 5.1 140 90 Emerg.LSCS 3.1 1  -  -  -  -  -  -  -
56 Selvarani 23 12351 Primi Severe Preeclampsia 36 3+ 1274 7.3 170 118 LN 1.1 1 1  -  -  - 1  -  -
57 umamaheshwari 37 2233 Primi Control 37 nil 217 3 110 76 Emerg.LSCS 2.45  -  -  -  -  -  -  -  -
58 Shalini 23 2171 G4P1L0A2Control 38 Trace350 3.6 130 76 Emerg.LSCS 2.4  -  -  -  -  -  -  -  -
59 Pavithra 21 2000 G2P1L1 Mild Preeclampsia 37 1+ 264 4.2 140 96 LN 2.35  -  -  -  -  -  -  -
60 Jayalakshmi 24 2085 G2P1L1 Mild Preeclampsia 37 1+ 640 6.8 150 100 Emerg.Rpt LSCS 2.25  -  -  -  -  -  -
61 Aaliyathabasum19 19 6484 Primi Eclampsia 37 4+ 1710 7.2 180 124 Emerg.LSCS 2.3 1 1  -  -  - 1 1
62 Vaishnavi 22 2292 G2P1L1 Control 38 Trace209 2.6 120 70 Emerg.Rpt LSCS 3.1  -  -  -  -  -  -  -  -
63 Suganthi 24 1719 G2P1L0 Control 37 nil 196 3.2 110 80 Emerg.LSCS 2.6  -  -  -  -  -  -  -  -
64 Mohana 27 2068 G2P1L1 Severe Preeclampsia 37 3+ 1056 6.6 170 108 Emerg.LSCS 1.7  - 1  -  - 1  -  -
65 Anitha 22 2335 Primi Severe Preeclampsia 37 2+ 540 6 156 110 Emerg.LSCS 2.2  -  -  -  -  -  -  -  -
66 Sandhya 28 2065 Primi Mild Preeclampsia 38 1+ 412 5.8 140 90 Emerg.LSCS 3.2  -  -  -  -  -  -  -  -
67 Sumathy 35 2635 G6P2L2A3Severe Preeclampsia 40 2+ 450 4.5 160 112 Emerg.LSCS 4.3  -  -  -  -  -  -  -  -
68 Anitha 20 2427 Primi Mild Preeclampsia 37 1+ 670 6.2 140 106 Emerg.LSCS 2.3  -  -  -  -  -  -  -  -
69 Yasodha 20 2301 G2P1L1 Control 40 nil 154 2.8 130 70 Emerg.Rpt LSCS 3.01  -  -  -  -  -  -  -  -
70 Soundarya 25 2306 Primi Control 40 nil 176 3.1 120 80 Emerg.LSCS 3.2  -  -  -  -  -  -  -  -
71 Pushpa 34 6152 Primi Severe Preeclampsia 34 3+ 1096 7 170 110 Emerg.LSCS 900g 1  -  -  -  -  -  -
72 Nagalakshmi 20 2461 Primi Mild Preeclampsia 39 1+ 593 6.3 150 96 Emerg.LSCS 2.4  -  -  -  -  -  -  -
73 Kalaivani 29 2436 G2P1L1 Control 39 Trace317 4.7 120 70 Emerg.Rpt LSCS 2.6  -  -  -  -  -  -  -  -
74 Suseela 24 2465 Primi Control 40 nil 162 3.2 120 76 Emerg.LSCS 2.8  -  -  -  -  -  -  -  -
75 Sugi 22 2291 Primi Severe Preeclampsia 36 3+ 880 7.1 170 120 Emerg.LSCS 1.2  - 1  -  -  -  -  -  -
76 Sajitha 22 2388 Primi Mild Preeclampsia 38 1+ 424 5.6 160 106 Emerg.LSCS 2.75  -  -  -  - 1  -  -
77 Jayanthi 21 2556 Primi Severe Preeclampsia 37 2+ 410 6.6 160 110 Emerg.LSCS 2.4  -  -  -  -  -  -  -  -
78 Jeevitha 22 2782 G2P1L1 Control 39 nil 170 2.6 120 80 Emerg.Rpt LSCS 2.9  -  -  -  -  -  -  -  -
79 Ramya 24 2577 Primi Severe Preeclampsia 35 3+ 740 6.8 180 120 Emerg.LSCS 1.75  -  -  -  -  -  -  -  -
80 Sujatha 23 2599 G2P1L1 Control 40 Trace212 4 120 74 Emerg.Rpt LSCS 3.5  -  -  -  -  -  -  -  -
81 Maheshwari 24 7101 Primi Eclampsia 34 4+ 1296 7.1 170 120 Emerg.LSCS 2.3  -  -  -  -  -  - 1  -
82 Shanthi 20 2757 Primi Mild Preeclampsia 36 1+ 620 5.7 150 108 Emerg.LSCS 1.5  - 1  -  -  -  -  -  -
83 Lakshmi 21 2754 G5P3L2A1Severe Preeclampsia 36 2+ 770 6.5 180 100 Emerg.LSCS 1.5  - 1  -  -  - 1  -  -
84 Rekha 28 2846 G3P1L2 Mild Preeclampsia 39 1+ 556 6.6 156 106 Emerg.LSCS 3.2  -  -  -  -  - 1  -  -
85 Valli 20 2609 G2P1L1 Control 38 trace317 5.2 130 80 Elective LSCS 2.45  -  -  -  -  -  -  -  -
86 Premalatha 22 2834 Primi Mild Preeclampsia 37 1+ 280 4.8 150 90 Emerg.LSCS 2.75  -  -  -  -  -  -  -  -
87 Victoria 25 2825 G2P1L1 Severe Preeclampsia 37 3+ 750 7.2 176 112 Emerg.LSCS 1.96  - 1  -  - 1  -  -
88 Vijayalakshmi 20 2920 Primi Mild Preeclampsia 40 1+ 280 5 140 102 Emerg.LSCS 2.4  -  -  -  -  -  -  -
89 Anbarasi 21 2600 Primi Control 39 nil 135 2.6 120 76 Emerg.LSCS 3  -  -  -  -  -  -  -  -
90 Jayashree 23 2663 Primi Control 40 nil 196 3 126 82 Emerg.LSCS 3.1  -  -  -  -  -  -  -  -
91 Thenmozhi 31 7211 G2A1 Severe Preeclampsia 35 3+ 1050 6.9 170 110 Emerg.LSCS 1.8  -  -  -  - 1  -  -  -
92 Shanthi 21 2880 Primi Mild Preeclampsia 38 1+ 350 5 150 90 Elective LSCS 2.75  -  -  -  -  -  -  -  -
93 Deepalakshmi 21 3479 G3A2 Severe Preeclampsia 37 2+ 617 6.1 156 112 Emerg.LSCS 2.6  -  -  -  - 1  -  -
94 Ramya 25 38416 Primi Mild Preeclampsia 37 1+ 280 4.2 160 100 Emerg.LSCS 2.75  -  -  -  - 1  -  -
95 Rajeshwari 24 2015 G2P1L0 Eclampsia 37 2+ 780 6.8 170 114 Emerg.LSCS 2.75  -  -  - 1  -  - 1  -
96 Priya 20 3515 Primi Control 39 nil 192 2.8 110 80 LN 2.5  -  -  -  -  -  -  -  -
97 Vanishree 25 3814 Primi Control 40 nil 205 3.1 120 82 Emerg.LSCS 3  -  -  -  -  -  -  -  -
98 Suganthi 30 3816 Primi Control 40 nil 217 3.2 112 74 LN 2.5  -  -  -  -  -  -  -  -
99 Ezhilarasi 24 3377 Primi Mild Preeclampsia 39 1+ 550 6.4 156 90 Emerg.LSCS 2.4  -  -  -  -  -  -  -  -
100 Banupriya 22 3227 Primi Mild Preeclampsia 38 1+ 406 5 140 96 Emerg.LSCS 2.6  -  -  -  -  -  -  -  -
101 Kanchana 26 7325 Primi Eclampsia 36 3+ 978 6.2 180 110 Emerg.LSCS 2  - 1  -  -  -  - 1  -
102 Sandhiya 23 3421 G2P1L1 Mild Preeclampsia 39 1+ 318 5.2 140 100 Emerg.LSCS 3.2  -  -  -  -  -  -  -  -
103 Asha 26 3439 Primi Mild Preeclampsia 38 1+ 340 4.9 130 94 Emerg.LSCS 3  -  -  -  -  -  -  -  -
104 Sumithra 20 3639 Primi Severe Preeclampsia 38 2+ 580 6.9 150 110 Emerg.LSCS 2.5  -  -  -  -  -  -  -  -
105 Vasanthi 21 3688 Primi Severe Preeclampsia 36 3+ 702 6.6 107 110 Emerg.LSCS 1.8  -  -  -  -  -  -  -  -
106 Mariammal 26 3595 Primi Control 37 Trace217 4.2 120 84 Emerg.LSCS 2.4  -  -  -  -  -  -  -  -
107 Anitha 26 3767 Primi Control 39 nil 180 2.2 120 76 LN 3.1  -  -  -  -  -  -  -  -
108 Saranya 24 3831 Primi Mild Preeclampsia 39 1+ 320 4.2 150 106 Emerg.LSCS 3  -  -  -  -  - 1  -  -
109 Hemavathy 22 3970 Primi Mild Preeclampsia 38 1+ 412 5.4 162 100 Emerg.LSCS 2.45  -  -  -  -  -  -  -  -
110 Malini 25 3838 Primi Control 40 nil 145 2.6 120 80 LN 3.1  -  -  -  -  -  -  -  -
111 Sudharsana 19 7825 Primi Eclampsia 34 4+ 1150 6.3 170 114 Emerg.LSCS 1.4  - 1  -  - 1  - 1  -
112 Vasantha 28 3995 G2P1L1 Severe Preeclampsia 36 4+ 1260 7.2 180 110 Emerg.LSCS 1.5  - 1  -  - 1  -  -  -
113 Nasreenbanu 19 1384 Primi Mild Preeclampsia 38 1+ 634 6.2 156 108 Emerg.LSCS 2.3  -  -  -  -  -  -  -  -
114 Kuppammal 24 3868 G2P1L1 Control 39 nil 180 2.2 110 76 LN 2.7  -  -  -  -  -  -  -  -
115 Rajeshwari 23 3842 G2P1L1 Control 39 Trace204 3.6 120 84 Emerg.Rpt LSCS 2.5  -  -  -  -  -  -  -  -
116 umamaheshwari 20 1623 Primi Severe Preeclampsia 36 3+ 620 6.5 170 112 Emerg.LSCS 1.8  -  -  -  -  -  -  -
117 Nalini 28 1923 G2P1L1 Mild Preeclampsia 37 1+ 470 5.8 140 106 Emerg.Rpt LSCS 2.3  -  -  -  -  -  -  -  -
118 Easwari 21 3833 Primi Control 39 nil 156 3.1 120 70 Emerg.LSCS 2.8  -  -  -  -  -  -  -  -
119 Annapoorani 20 1822 Primi Severe Preeclampsia 38 2+ 1256 6.7 160 120 Emerg.LSCS 2.5  -  -  -  - 1  -  -
120 Sathyabama 27 3869 G2P1L1 Control 39 nil 317 4 130 70 Emerg.Rpt LSCS 2.8  -  -  -  -  -  -  -  -
121 Nirosha 25 3754 Primi Control 40 nil 194 2.8 120 76 LN 2.8  -  -  -  -  -  -  -  -
122 Vasanthi 21 3882 G2P1L1 Control 40 nil 172 2.6 110 74 LN 3.5  -  -  -  -  -  -  -  -
123 Vijaya 25 1844 G2P1L1 Eclampsia 36 4+ 986 6.8 184 114 Emerg.LSCS 2.2  -  -  -  -  -  - 1  -
124 Nandhini 27 1928 G3P1L1A1Mild Preeclampsia 37 1+ 360 5.5 146 94 Emerg.Rpt LSCS 2.3  -  -  -  -  -  -  -  -
125 Deepalakshmi 21 3479 G3A2 Mild Preeclampsia 37 1+ 626 5.2 156 104 Emerg.LSCS 2.6  -  -  -  - 1  -  -
126 Gayathri 21 2039 G2A1 Control 37 Trace354 4.4 130 80 LN 2.3  -  -  -  -  -  -  -  -
127 Pushparani 28 3658 G2P1L1 Severe Preeclampsia 36 3+ 440 6.1 160 110 Emerg.Rpt LSCS 1.9  -  -  -  -  -  -  -  -
128 Nadhiya 26 3640 Primi Mild Preeclampsia 37 1+ 317 5.4 150 94 Emerg.LSCS 2.4  -  -  -  -  -  -  -  -
129 Sumathy 25 3881 G2P1L1 Control 38 nil 166 2.8 110 70 LN 2.7  -  -  -  -  -  -  -  -
130 Shridevi 24 3636 Primi Severe Preeclampsia 38 2+ 745 6.5 160 112 Emerg.LSCS 2.1  - 1  -  -  -  -  -  -
131 Poongodi 26 3847 Primi Control 40 nil 150 2.7 126 76 LN 3.3  -  -  -  -  -  -  -  -
132 Shrividhya 26 3671 Primi Severe Preeclampsia 39 2+ 420 6.1 160 112 Emerg.LSCS 3.75  -  -  -  -  -  -  -  -
133 Naviselvi 25 3495 G3P2L2 Severe Preeclampsia 32 4+ 780 6.7 130 110 LN 1  -  -  -  -  -  -  -
134 Nagavalli 20 3848 G2P1L1 Control 38 Trace226 3.2 130 70 LN 2.5  -  -  -  -  -  -  -  -
135 Nagalakshmi 28 3987 G3P12L1 Mild Preeclampsia 37 1+ 510 6.8 150 96 Emerg.Rpt LSCS 2.1  -  -  -  -  -  -  -  -
136 Arunadevi 25 3884 Primi Control 36 nil 194 2.1 120 90 Emerg.LSCS 2.1  -  -  -  -  -  -  -  -
137 Umadevi 23 14956 Primi Severe Preeclampsia 35 3+ 710 6.2 140 110 Emerg.LSCS 1.2  - 1  -  -  -  -  -  -
138 Samandhi 24 3791 Primi Mild Preeclampsia 38 1+ 752 6.3 150 104 Emerg.LSCS 1.75  - 1  -  -  -  -  -  -
139 Navamani 33 3740 G2P1L1 Control 38 Trace260 2.8 130 76 Emerg.Rpt LSCS 2.45  -  -  -  -  -  -  -  -
140 Najumunisha 22 3890 Primi Control 39 nil 162 2.5 120 70 LN 2.9  -  -  -  -  -  -  -  -
141 Gayathri 22 3802 G2P1L0 Mild Preeclampsia 37 1+ 380 4.7 150 94 Emerg.Rpt LSCS 2.6  -  -  -  -  -  -  -  -
142 ParveenBanu 24 3032 G4P2L1A1Severe Preeclampsia 34 3+ 940 7.1 160 110 LN 1.5  - 1  -  -  -  -  -  -
143 Ramani 30 3748 G2P1L1 Control 37 nil 240 3.1 120 72 Emerg.Rpt LSCS 2.5  -  -  -  -  -  -  -  -
144 Varnalatha 24 3914 Primi Eclampsia 34 3+ 1120 6.3 176 112 Emerg.LSCS 1.75  - 1  -  -  -  - 1  -
145 Kasinabegum 34 12142 Primi Severe Preeclampsia 35 2+ 755 6.6 170 112 Emerg.LSCS 2  -  -  -  -  -  -  -  -
146 Vasanthi 21 12764 Primi Eclampsia 37 4+ 1350 7 180 120 Emerg.LSCS 1.75  - 1  -  -  -  - 1  -
147 Suseela 23 3416 G2P1L1 Control 39 Trace405 5.1 130 86 LN 2.5  -  -  -  -  -  -  -  -
148 Dilshath 22 14068 G3P1L1A1Severe Preeclampsia 36 3+ 1226 6.5 160 120 Emerg.LSCS 1.9  - 1  -  - 1  -  -
149 Jothika 20 3924 Primi Control 40 nil 312 2.8 112 74 LN 3.2  -  -  -  -  -  -  -  -
150 Sangeetha 25 3939 Primi Control 39 nil 270 3.2 118 80 LN 2.7  -  -  -  -  -  -  -  -
151 umamaheshwari 21 13286 Primi Eclampsia 38 4+ 1359 7.2 190 116 Emerg.LSCS 1.6  - 1  -  -  -  - 1  -
152 Sathya 24 14216 Primi Severe Preeclampsia 34 2+ 1056 6.6 166 110 Emerg.LSCS 1.5  - 1  -  -  -  -  -  -
153 Komala 24 3932 Primi Control 39 nil 220 2.2 120 74 Emerg.LSCS 2.6  -  -  -  -  -  -  -  -
154 Revathy 21 8283 Primi Severe Preeclampsia 38 3+ 770 6.8 160 120 Emerg.LSCS 2.2  - 1  -  - 1  -  -
155 Angelchristy 24 14197 Primi Eclampsia 38 2+ 866 6.8 170 110 Emerg.LSCS 2.1  - 1  -  -  -  - 1  -
156 Vijayashree 22 3971 Primi Control 37 nil 366 3.6 130 76 Emerg.LSCS 2.4  -  -  -  -  -  -  -  -
157 Kirija 24 8330 Primi Severe Preeclampsia 36 2+ 468 6 150 110 LN 2.3  -  -  -  -  -  -  -  -
158 Santhanamary 21 8413 Primi Mild Preeclampsia 37 1+ 376 5.2 156 90 Emerg.LSCS 2.25  -  -  -  -  -  -  -  -
159 Maragatham 21 2080 Primi Mild Preeclampsia 39 1+ 334 6.2 150 100  Emerg. LSCS  Emerg.LSCS 3  -  -  -  -  -  -  -  -
160 Monika 20 3973 Primi Control 38 nil 245 3.2 120 80 LN 2.5  -  -  -  -  -  -  -  -
161 Maha 23 2418 Primi Severe Preeclampsia 38 2+ 716 7.3 166 112 Emerg.LSCS 2.2  - 1  -  -  -  -  -  -
162 Divya 24 2654 Primi Severe Preeclampsia 35 3+ 1026 7.2 170 120 Emerg.LSCS 1.4  - 1  -  -  -  -  -  -
163 Indhu 21 2808 Primi Severe Preeclampsia 39 2+ 509 6.4 160 110 Emerg.LSCS 3.5  -  -  -  -  -  -  -  -
164 Sundaravalli 21 3450 Primi Severe Preeclampsia 36 2+ 527 5.8 150 116 Emerg.LSCS 2.3  -  -  -  -  -  -  -  -
165 Kanagavalli 22 836 G2A1 Severe Preeclampsia 37 3+ 720 6.4 162 110 Emerg.LSCS 2.3  -  -  -  -  - 1  -  -
  
  
  
 
 
 
 
